Lei Jiayin’s "In the World" has gained a high popularity and a good reputation. The play has not yet ended, and Lei Jiayin’s "Meeting Time" has been broadcast. In the beginning of 2022, Lei Jiayin has one after another "heavyweight" plays to meet the audience, which is really rare.

Different from "In the World", after the broadcast of "Meet Time", the word-of-mouth was mixed. However, the audience still recognized the acting skills of the leading actor in the play. In addition to the heroine Yolanda, there are two female characters in Meet Time, who are in great contrast but have bright spots.

Jane Minmin, played by Luo Haiqiong, is a "comedian" in the play, while Chen Xiner, played by Lian Lian, is a "tragic person". The fate of the two roles is different, which left a deep impression on the audience.

In Meet Season, Jane Minmin is Jane Hongcheng’s sister. She dropped out of school at the age of 18, and later married Zhang Lixin for the sake of her family’s factory. When her father died, Jane Minmin kicked her brother Jane Hongcheng out. Twenty years later, Jane Minmin has no real power in the factory, and she lives a pampered life every day. Jane Minmin, who is out of touch with society, has no domineering when she was young, but has a lovely contrast.

Not very smart, but also want to do things, and was fooled by a so-called investor. The middle-aged Jane Minmin was played by Luo Haiqiong, who was also a proper comedian in the play Meet Time. Every time Jane Minmin appeared, she was very funny, which made the audience laugh. Luo Haiqiong’s acting skills are very good, and there are many nonsense performances in Jane Minmin’s plays. However, because of the proper scale, Luo Haiqiong’s performance is not embarrassing, but makes people feel humorous.

Luo Haiqiong used to be one of the "Four Little Tsing Yi". When he was young, he was beautiful and good at acting. In such plays as Fog Like Rain and Wind, and Song Dynasty, Luo Haiqiong’s performance left a very deep impression on the audience.

In 2010, Luo Haiqiong married the vice-president of Huayi Brothers, and Luo Haiqiong’s film and television dramas, which were married into the rich family, became less and less. However, whether it was Kite, Hunting Field or Meet Time, even though there were not many scenes, Luo Haiqiong was able to make his characters glow with superb acting skills, which was very rare.

If Jane Minmin is a "comedian" in "Meet Time" and practices her role as Chen Xin ‘er, it is a "tragic person" in the play.

In Meet Season, Jane Hongcheng and Ning Yi had a love affair, but because of the hatred of their parents, the relationship ended in vain.

Chen Xin ‘er, Jane Hongcheng and Ning You were college classmates. Later, she married Jane Hongcheng, but their marriage didn’t last long. In the end, they had no choice but to divorce. Although divorced, Chen Xiner has always loved Jian Hongcheng deeply, and she has always regarded Ning Yi as her imaginary enemy, constantly calling and harassing Ning Yi, and even hearing that Ning Yi is divorced, she also wants to prevent Jian Hongcheng from being with Ning Yi by suicide.

I can’t love, and I am crazy about love, especially after I get married and don’t go out to work. In Meeting Season, Chen Xiner really lives a humble life and is very wronged. It is no exaggeration to say that she is the most pathetic woman in Meeting Season.

Chen Xiner is starring in the actor’s practice, with high face value and good acting skills. The practice will make Chen Xiner, who is neurotic and unlovable, very vivid. "Meet Time" is not the first time that Lian Lian has cooperated with the midday sunshine. In "Big Rivers", Wei Chunhong, played by Lian Lian, also left a deep impression on the audience.

In fact, both Luo Haiqiong and Lian Jian have rich performance experience. In Meet Time, Jane Minmin and Chen Xin ‘er are two women with completely different personalities. Luo Haiqiong and Lian Jian also have a good grasp of the role, so are good actors. What they play is like, and small roles can also make the audience see the bright spots. This is the skill of powerful actors.

Although there is no problem with the actors’ acting skills in Meeting Season, there are still voices in the plot, such as Jane Minmin and Chen Xin ‘er, whose characters in the play are very disliked by some audiences, whether it is "comedian" Jane Minmin, "tragic person" Chen Xin ‘er or "virgin Mary’s heart" Ning Yi. If there is a favorite audience, there will be an audience who is annoyed by God.

Source: vision china

In 2000, 10,000, 50,000 … In just five minutes, more than 50,000 people flooded into Qier’s live broadcast room, and the number of online users continued to grow. The anchor Qier also has a louder identity, which is Viya’s assistant. She sits on the left side of Viya all the year round and is an old face in the live broadcast room of Viya.

In fact, as early as April 13th, Qier held three live broadcasts in Tik Tok one after another. "Don’t even think about it, it must be warming up for the goods," said Mumu (a pseudonym), an old powder in the live broadcast room in Viya, to Time Finance. Since the tax turmoil in Viya, Qier’s personal account in Tik Tok has been cut off for more than 160 days.

To a certain extent, Qier’s comeback borrowed the popularity of Viya, and the number of online people in the live broadcast room peaked at more than 90,000 that night, and the first broadcast was the first on the list. However, the collapse of trust caused by tax evasion is difficult to recover. At the end of the live broadcast, she said: "It will be broadcast for a long time, and I hope fans can trust the team."

Another familiar face came, and a live broadcast rose by 200,000 yuan.

After Viya disappeared for half a year, her "cronies" gradually returned to the live broadcast room.

Qier’s comeback had a clue. When Viya helped broadcast a six-member group to form the Bee Welfare Society, only Qier, the second person in the live broadcast room, was missing. At the beginning, fans asked about Qier’s whereabouts.

After this comeback, Qier’s "configuration" is much higher than that of Bee Welfare Society. She is the only protagonist in the live broadcast room, sitting in the C position of the live broadcast screen, and playing the IP of the personal live broadcast room of "Qi Miao Meeting Ceremony".

Undoubtedly, Qier’s live broadcast room gathered the common expectation of Viya fans, "Waiting for your live broadcast", "A part of my life is back" and "More maternity products" they commented in Qier’s updated short video.

"Pay attention to the live broadcast room, first draw the prize" and "I’m back" were accompanied by shouts, and Mu Mu opened the live broadcast room at the first time. "It’s the same formula as Viya’s team, and many of the selected products are explosions from the previous live broadcast room".

Time Finance found that the rhythm and style of Qier’s live broadcast are in the same strain as Viya’s, and the selection still consists of four categories: beauty and skin care, life, clothing and food, which is in line with the positioning of Viya’s live broadcast room as a large-scale lifestyle supermarket. In addition, Qier also established the official WeChat official account of Qier Surprise Club, which was used to announce live broadcast products and build a personal fan base.

A total of 85 products were put on the live broadcast that night, but the inventory of products was not too much. Most products were stocked with less than 10,000 copies, and the single product with the highest sales volume sold 15,400 pieces that night.

From Taobao to Tik Tok, the live broadcast also changed with the rules. Viya’s former home was Taobao, which meant that it was difficult for some fans to migrate, and it also made Qier, who became the protagonist in the live broadcast room for the first time, feel a little pressure.

During the five-hour live broadcast, the staff of the live broadcast room repeatedly asked the fans for the purchase steps of the popular science live broadcast room, and Qier said no less than 10 forbidden words, including "whitening special certificate" and "seconds kill". During the halftime, Qi ‘er’s voice began to hoarse. After she changed from assisting broadcasting to becoming a regular member, she was faced with a heavier workload and more intensive oral broadcasting.

"You can’t put eggs in one basket. Qianxun also has the idea of building a talent on the whole platform, which can form a more complete live broadcast matrix. For the newcomer anchor, the short video of vibrato will have better drainage effect and attract fans outside the original traffic in Viya. " An insider of an MCN organization told Time Finance.

According to the data of red people’s point set, the total sales of Qier’s live broadcast room that night was 18.2303 million yuan, the total viewing volume reached 6.0567 million, and a live broadcast rose more than 200,000. As a new anchor, this achievement is undoubtedly beyond expectations, but compared with Viya’s sales of hundreds of millions of yuan, Qier is a big gap.

The assistant turned positive, and the "body double" in the Viya live broadcast room

Qier’s bold comeback may draw lessons from the success of Bee Welfare Society.

After 85 days of debut, Bee Welfare Society has formed a stable live broadcast rhythm and audience. Time Finance found that in the past two months, the number of viewers in its live broadcast room has stabilized at 7-8 million, and it has squeezed into the top three positions in Taobao’s live broadcast room.

It is understood that the registered addresses of Viya’s husband Dong Haifeng’s Hangzhou Lanhai Enterprise Management Consulting Company and Hangzhou Fenghan Enterprise Management Co., Ltd. are on different floors in Jiangjin International Building, Binjiang District, Hangzhou, as well as the registered address of Hangzhou Baifeng Culture Media Co., Ltd., a certification company of Bee Surprise Society.

Compared with the composition of the bee welfare society, Qier’s identity is more special. During the three years that Viya was active in the live broadcast room, Qier’s schedule almost completely coincided with Viya’s, and they were inseparable. Viya once said, "I spend more time with Qier than with my husband". Another important identity of Qier is the girlfriend of Viya’s younger brother and fourth brother, and also Viya’s best friend for nearly ten years.

It can be seen that both Bee Surprise Club, which was the first to test the water, and Qier’s personal live broadcast room are inextricably linked with Viya and Qianxun Company behind it. The "women" in Viya firmly believe that Viya is responsible for their live selection and supply chain.

It is not Viya’s initiative to help broadcast hold up half the sky. The Simba family has hatched a number of popular anchors in the form of mentoring, including balls and cat sisters. Now, Simba has retired from the live broadcast of rivers and lakes, and undertaken behind-the-scenes work such as supply chain construction and anchor incubation. Simba’s apprentice Dan Zi won the baton, became the number one anchor of the family, and repeatedly topped the list of people with goods in Aauto Quicker.

With the anchor tax investigation, a cruel fact is in front of us. The relationship between the head anchor and MCN company is "one glory and one loss". If we don’t train successors, MCN company is likely to face the embarrassing situation that no one is available.

As another big traffic pool, Li Jiaqi, the first brother of Taobao, is also laying out his own help matrix.

As early as two years ago, the United States one had the consideration of righting the broadcast. At that time, Fu Peng, a little assistant with a strong sense of existence in the live broadcast room in Li Jiaqi, chose to fly solo, relying on the popularity of Li Jiaqi to quickly accumulate the first fans, and started the live broadcast with goods on the platform of Little Red Book. However, one year later, Fu Peng’s live broadcast with goods came to an end. At this time, US ONE urgently needed another IP to continue the traffic in Li Jiaqi.

Since the second half of last year, Li Jiaqi’s broadcasting assistance team has continuously expanded its enrollment, and now it has formed a 7-member broadcasting assistance group, and its influence scope is also constantly expanding. "Li Jiaqi Fashion Broadcasting Group" has its own accounts in Weibo, Tik Tok, bilibili and other platforms. At present, its little red book account has 98,000 fans and 132,000 likes.

It has become a trend in the live broadcast industry to help broadcast to become an anchor. The logic behind it is still based on the big IP effect of the head anchor, holding and expanding the original traffic disk.

But it’s also a hard road. "Viya’s red burst is the result of multiple factors, and now the combined traffic of the two teams is hard to exceed her." Mu Mu sighed to Time Finance.

1905 movie network news The Netflix movie Parade, which was directed by the original script of "Ten Years Left", released its first preview on February 6th. At the same time, official Xuanye Tanjiro produced and sang the theme song "なみしぐさ" for the film. The film attracted the first-line actors from Japan, such as Japan, Japan, Japan, Japan, Japan, Japan, etc., and the lineup was brilliant.

From the perspective of the deceased, this film depicts their feelings and attachment to the living: a joyful tour to explain the bereavement experience, accepting the inevitable grief of life frankly, and evoking all kinds of memories of the audience’s love. Minako (Masami Nagasawa), the hero, is still attached to the world after her death. She gathers the dead together once a month and holds a "parade" to find the people she wants to see.

Masami Nagasawa plays Minako, who is looking for his only son Liang. Sakaguchi Kentaro plays Akira, a melancholy literary youth, Yokohama ryusei plays Victory, a former gangster, Lily Francci plays Michael, a former film producer, Kaori, Tetsushi Tanaka plays Tanaka, a former bank clerk, and Mori Qicai plays Nana, a female high school student who is desperate for survival. There are also,, Ruolin Tuoye,, Denden, Guan Guang (special performance),, and Aoping Da.

The movie Parade will be launched on Netflix on February 29th!

Poster of "the escapee"

　 　 1905 movie network news 　The suspense spy TV series "The Escape" has recently announced that Chen Kun will return to the TV screen to play the leading role in the drama. Today, the official Weibo officially announced the winner of the Golden Horse Award for the leading actress — — Wan Qian, a powerful actress. It is reported that the play will start in December.

"Beauty and acting" is the criterion for actor selection.

　 　 As an original spy war drama, Chen Kun once said that the screenwriter was very attentive and spent nine years polishing the script repeatedly. The script and characters were the main reasons that moved him to return to the TV screen after nine years.

　 　 Since it was announced that Chen Kun would star in The Escape, the media and fans have been very concerned about the heroine’s choice. Who can Hold Chen Kun who is both an acting school and an idol school? Many fans have also launched heated discussions and suggestions on Weibo. Judging from the comments of netizens, the choice of "acting school" is the most popular.

The voice of fans　

　 　 As a spy war drama, gripping stories and actors’ acting skills are the magic weapon to win the spy war drama. The drama side said that "The Escape" will focus on the selection criteria of "having face and acting skills", and gather domestic actors with both face value and strength, as well as the best production team to jointly create a boutique spy war drama.

Wan Qian joins in and expects the powerful faction to "play"

Wan Qian; Regina

　 　 Wan Qian, a newly rising powerful actress, won the "Best Supporting Actress" in the 51st Golden Horse Award of Taiwanese Film for her role of "Nini". Two films starring Wan Qian and Hello, Crazy! Will be released in the near future.

　 　 Coincidentally, last weekend’s "Hello, Crazy! At the screening meeting, Chen Kun attended the event and praised Wan Qian’s performance. He not only used the word "shock" to describe Wan Qian’s real performance, but also revealed that he was deeply impressed by Wan Qian’s performance after watching the rough cut of the film a few months ago, hoping to invite Wan Qian to participate in his new play. It seems that apart from the role relationship and plot development of the two people, the drama of the two people will also be a major attraction in The Escape.

　 　 Wan Qian also said that it is a great honor to play The Escape with Chen Kun: "The script that The Escape took nine years to create is very exciting. I am very happy to participate in it. I am looking forward to working with Brother Kun. The next task is to play my role well and live up to everyone’s expectations."

Tencent Video

Youku

Iqiyi

1905 movie network news Today’s news, the three major video portals, iQiyi, Tencent and Youku, issued a joint announcement to jointly resist inferior artists and jointly take the first step in the healthy management of video websites. The following is the text of the announcement.

As can be seen in the announcement, the three major video portals have noticed some worrying phenomena, and the "star effect" has been exaggerated; A small number of actors’ own behaviors are not standardized, which makes the original orderly creative environment appear disharmonious and unhealthy. For example, some actors’ "value-only theory" violates the market rules and offers sky-high pay, so they no longer concentrate on creation; The studio is passive and does not work according to the specified time; The "position-only theory" disrespects other creative members of the crew, puts forward abnormal requirements, alters scripts indiscriminately, interferes with the director’s shooting, and decides the actor’s collocation and replacement.

In addition, the announcement also emphasized that actors should be prevented from forcibly appointing co-directors, co-actors, deleting scripts and deciding their positions in order to highlight their personal scenes and not respecting the main context of script creation and the performances of other actors; Put an end to the phenomenon that actors don’t work hard to ensure the normal operation of the crew; Even, we will gradually establish a list of bad actors, including actors who violate the spirit of contract, misbehave, are not dedicated, put forward unreasonable demands, and disturb the normal shooting order of the crew. The three platforms will implement an early warning mechanism for such actors and employ them cautiously.

I don’t know if you "bad artists" are worried now.

CCTV News:National Health Commission informed, September 21, 0— At 2400 hours, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 165 newly confirmed cases. Among them, there were 51 imported cases (13 cases in Guangdong, 9 cases in Shanghai, 6 cases in Beijing, 6 cases in Yunnan, 5 cases in Inner Mongolia, 3 cases in Fujian, 3 cases in Sichuan, 2 cases in Shaanxi, 1 case in Tianjin, 1 case in Heilongjiang, 1 case in Jiangsu and 1 case in Shandong), including 8 cases from asymptomatic infected people to confirmed cases (2 cases in Beijing, 2 cases in Guangdong, 2 cases in Sichuan, 1 case in Inner Mongolia and 1 case in Shandong). There were 114 local cases (42 cases in Guizhou, 41 cases in Sichuan, 13 cases in Tibet, 7 cases in Heilongjiang, 4 cases in Ningxia, 3 cases in Henan, 1 case in Tianjin, 1 case in Zhejiang, 1 case in Fujian and 1 case in Guangdong), including 23 cases from asymptomatic infected persons to confirmed cases (18 cases in Sichuan, 3 cases in Guizhou, 1 case in Zhejiang and 1 case in Guangdong). There were no new deaths. There are no new suspected cases.

On that day, 279 new cases were cured and discharged, including 45 imported cases and 234 local cases (Sichuan 113 cases, Tibet 27 cases, Guangdong 24 cases, Hainan 10 cases, Guizhou 8 cases, Liaoning 7 cases, Heilongjiang 7 cases, Guangxi 7 cases, Beijing 6 cases, Inner Mongolia 6 cases, Shandong 4 cases, Qinghai 4 cases, Chongqing 3 cases, Jilin 2 cases, Tianjin 1 case and Tianjin 1 case).

There are 577 confirmed cases (no severe cases) imported from overseas, and there are no existing suspected cases. A total of 23,578 cases were diagnosed, and 23,001 cases were cured and discharged, with no death.

As of 24: 00 on September 21st, according to the reports of 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps, there are 3,183 confirmed cases (including 35 severe cases), 240,400 discharged cases have been cured, 5,226 cases have died, and 248,809 confirmed cases have been reported, and there are no existing suspected cases. A total of 5,865,543 close contacts were tracked, and 151,003 close contacts were still under medical observation.

Thirty-one provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 610 new cases of asymptomatic infections, including 98 imported cases and 512 local cases (Tibet 143 cases, Guizhou 134 cases, Heilongjiang 109 cases, Sichuan 26 cases, Hubei 19 cases, Guangxi 15 cases, Ningxia 15 cases, Tianjin 10 cases, Xinjiang 9 cases, Henan 6 cases, Chongqing 5 cases, and Chongqing 5 cases).

On that day, 1,331 asymptomatic infected people were released from medical observation, including 90 imported cases and 1,241 local cases (513 in Tibet, 186 in Guizhou, 110 in Heilongjiang, 82 in Liaoning, 80 in Guangxi, 56 in Sichuan, 34 in Jiangxi, 33 in Xinjiang, 32 in Shandong, 26 in Hubei, 14 in Hainan, 13 in Guangdong and 12 in Tianjin). On the same day, 31 cases were converted into confirmed cases (8 cases were imported from abroad); There are 14,776 asymptomatic infected people under medical observation (766 cases imported from abroad).

A total of 6500010 confirmed cases were reported from Hong Kong, Macao and Taiwan. Among them, there were 408,844 cases in Hong Kong Special Administrative Region (81,888 cases discharged from hospital and 9,917 cases died), 793 cases in Macao Special Administrative Region (787 cases discharged from hospital and 6 cases died) and 6,090,373 cases in Taiwan Province (13,742 cases discharged from hospital and 10,643 cases died).

　　CCTV News:Diabetes is one of the common chronic diseases, and modern medicine can’t cure diabetes, so diabetics have to take medicine for life. However, in Taizhou, Zhejiang, an online shop claimed that there was a food that could lower blood sugar instead of drugs, and the local market supervision department launched an investigation.

　　In the name of consumers, the inspectors bought all the suspicious goods being sold in this online store. As can be seen from the appearance, Renhe Yibao Capsule, which is nominally jointly supervised by China Academy of Chinese Medicine and the Second Military Medical University of China People’s Liberation Army, indicates that it can remove drug toxicity and repair islets; The highest-priced product in online stores, which is called insulin II, claims to have American technical support and is supervised by the Diabetes Research Center of the American Military Medical College. It is a product sold only in Chinese mainland. In addition, the packaging boxes of these commodities are also printed with the approval number of the national food health food, which is known to consumers as "police tactical unit". After verification by inspectors, these approval numbers are all false, and the factory name and address on the packaging boxes can’t correspond. For further analysis and verification, the inspectors sent the goods to professional testing institutions for further testing and analysis.

　　Test results; Most fake health products contain western medicine ingredients.

　　Along this line of thought, the inspectors made a specific testing plan, and screened 11 kinds of drugs corresponding to diabetes one by one. It was found that these health foods all contained western medicine ingredients to varying degrees.

　　Among the 19 samples tested, 14 samples were found to contain western medicine, of which 8 samples contained phenformin hydrochloride, and the other 6 samples also contained glibenclamide and metformin hydrochloride.

　　It is understood that both phenformin hydrochloride and glibenclamide are prescription drugs that inhibit moderate type 2 diabetes and have a certain insulin secretion function. According to the clear provisions of China’s Food Safety Law, health food as food should not be added with drugs; At the same time, the label description of health food should not involve the expression of disease prevention and treatment functions. These health foods that claim to have hypoglycemic effect are not only found to contain western medicine ingredients, but also use false "national food health word" health food numbers, which are typical counterfeit health foods, so the actions of their producers and operators have been suspected of breaking the law.

　　Layers of distribution captured many suspects.

　　After confirming the existence of illegal acts, the inspectors immediately inquired about the online shop operator, and the owner provided the clue that the supplier lived in Henan Province. The inspectors immediately set up a task force with the local public security department to control the supplier in gongyi city, Henan Province.

　　The supplier purchased 400,000 yuan in less than one year.

　　According to the supplier Zhou Pengwei, he didn’t know the identity of the supplier. Both parties contacted and delivered the goods through WeChat. In less than a year, he accumulated five varieties and more than 400,000 yuan in goods from this supplier. After continuous monitoring, the electronic data forensics center in State Administration for Market Regulation, Taizhou, Zhejiang Province, monitored that this family landed in Zhengzhou, Henan Province.

　　After investigation, Yang Jiandong and his wife set up a courier company, but it is strange that the courier company has almost no business and can’t deliver several packages a day. By checking the express list of dozens of boxes of goods collected from Zhou Pengwei, the case-handling personnel locked a shipper named Zhu Xiangna, and finally determined that the goods were sent from the underground storage room of Zhu Xiangna’s garage.

　　National wholesalers sell hundreds of thousands of fake health products every month.

　　The case-handling personnel combined with the local public security department to take the action of closing the net, confirming that Zhu Xiangna is the top seller of Zhou Pengwei’s sales channel and a wholesaler facing the whole country. She mainly sells through WeChat group, and the average monthly cargo volume is about 200,000 yuan or so.

　　Through the clues provided by the delivery truck driver, the case-handling personnel arrested Liu Wei, the owner of toxic and harmful counterfeit health food, in zhongmou county. In his production and processing site, you can see that a large number of packaged capsule plates and semi-finished raw material powders are stored here, and about 700,000 health food capsules that have been produced but not yet sold have been collected on the spot. He sent more than 2 million pieces of goods to Zhu Xiangna and Yang Jiandong, and the accumulated sales amount was about 200,000 yuan.

　　Tracing back to the fact that the raw materials of western medicine actually came from regular pharmaceutical factories.

　　According to the owner’s account, the main raw material in capsule production is western medicine powder, which was consigned to him by a man named Zhang Xinglin in Bozhou, Anhui. The investigators conducted a basic information search on Zhang Xinglin, and found that this person had a record of manufacturing and selling counterfeit drugs.

　　Western medicine raw materials are disguised as fish food.

　　Zhang Xinglin frequents five places: the actual residence, the domicile, a farm house in a remote suburb, a consignment station and a Chinese medicine factory. He occasionally goes to the Chinese medicine factory to buy some Chinese medicine powder packed in yellow snakeskin bags, and occasionally sends it to the consignment station. From the consignment note, the goods he sends are marked as fish food. Zhang Xinglin, who was consigning drug powder, was arrested by the investigators at the freight station. In the warehouse where the investigators led Zhang Xinglin to identify the scene involved, we can see that boxes of western medicine glibenclamide tablets have not been opened, snakeskin bags filled with Chinese medicine powder are piled up in the corner, and there are many drums filled with white powder. At the unpacking and processing point, empty bottles of western medicine are all over the floor, so they are piled up in a corner of the house. After checking by inspectors, there are as many as 320,000 empty bottles of western medicine collected at the processing point in Zhang Xinglin.

　　Fake health food processing sites are extremely dirty.

　　Entering another processing point, the dirty scene in front of us makes it impossible to imagine that this is actually a place for processing health food raw materials. Bags of various fine particles that Zhang Xinglin himself can’t tell apart are piled all over the floor. The collected western medicine particles are beaten into powder on such a machine, and then the powder is mixed with various other powders at will with such a tool and roughly stirred, so that it can be packed into barrels and become the finished powder sold to the next family, and that bag is packed in snakeskin bags.

　　Some of the raw materials involved came from regular pharmaceutical factories.

　　Zhang Xinglin confessed that the western medicine powder he sold was sold to Liu Wei at the price of 80 yuan per kilogram. In more than a year, the sales amount of powder and raw materials he sold to Liu Wei totaled more than 200,000 yuan. In the warehouse in Zhang Xinglin, the investigators collected 25 boxes of unopened glibenclamide tablets. After searching the batch numbers of these drugs and checking with the manufacturers, it was confirmed that they were all genuine western medicines produced by regular pharmaceutical factories. According to this clue, the case-handling personnel arrested Li Panpan, a supplier who was not qualified for drug business, in Taihe County, Anhui Province. At this point, the case of manufacturing and selling toxic and harmful counterfeit health food covering the whole country was completely solved.

　　Fabricate the number of "national food health word" for profiteering

　　After the suspect arrived at the case, he confessed the facts of the crime. They packaged the food containing pharmaceutical ingredients into health food, fabricated a number of "national food health word" and sold it to the outside world. According to Zhu Xiangna, the reason why their products sell so much is because the effect of lowering blood sugar in the beginning is very obvious, so most of these buyers will buy back.

　　Glibenclamide is a chemical that specifically inhibits moderate type II diabetes. Each bottle contains 100 such small tablets, each of which is only 2.5 mg. The instructions for taking glibenclamide indicate that normal patients can only take one tablet a day, and those with mild symptoms can only take half a tablet a day. Inspectors said that through the whole production and processing process of counterfeit products, it can be known that the biggest risk faced by consumers lies in the uneven amount of drugs added in these health foods, which may lead to the occurrence of hyperlactaemia or lactic acidosis in the light, and even sudden death in the severe cases.

　　Inspectors also said that there is almost no continuous brand management of such health food. Basically, the same product name and packaging are printed hundreds or one or two thousand boxes at a time, and then other product names and packaging are changed after use. Even the production address and the serial number of "National Food Health Word" are printed at will.

　　The reporter randomly found a pharmacy and found glibenclamide tablets on the counter in the prescription drug section. A bottle of 100 tablets was packaged, and the retail price was 2.5 yuan. Zhang Xinglin bought glibenclamide tablets from Li Panpan in boxes according to the wholesale price, and the traceable drug cost has reached more than 300,000 yuan. Zhang Xinglin sold the western medicine powder to the manufacturer Liu Wei at the price of one kilogram of 80 yuan. Liu Wei mixed and stirred the western medicine raw materials, filled them into capsules, packed them in boxes of various brands, and sold them to Zhu Xiangna, Yang Jiandong and others at the price of 12.5 yuan. They wholesale to agents including Zhou Pengwei at the price of 30-35 yuan in WeChat group, and the agents like Zhou Pengwei sell them to dealers like Zhang Liangbo at the price of 45-50 yuan. By the time these toxic and harmful health foods illegally added with western medicine reach consumers, the price of each box has increased to 125 yuan.

　　In order to avoid supervision, these people who manufacture and sell toxic and harmful counterfeit health foods will use the increasingly developed network to reduce the relevance of each link, and at the same time use virtual identities to complete transactions and money transfers, which makes it extremely difficult to handle cases. To this end, the market supervision department and the public security department have formulated a system of linking case investigation and execution, tracing every small clue to the source and checking it to the end.

　　This mega-case of producing and selling toxic and harmful hypoglycemic health foods eventually arrested 13 suspects. Through this crackdown, the market supervision department smashed 10 production, sales and storage dens and seized more than 100,000 boxes of counterfeit health food, with a case value of 1.6 billion yuan.

I. Basic financial data

Data is rounded to see more financial data > >

Second, the dividend delivery scheme

Rmb 0.130 per share

III. Business Review and Prospect

　　I. Discussion and analysis of business conditions

　　The year 2021 is the year when China has built a well-off society in an all-round way, and it is also the first year of the 14 th Five-Year Plan. Standing at the historical intersection of the goal of "two hundred years", facing the global COVID-19 epidemic and the national joint "purchasing with quantity" environment, under the strong leadership of the board of directors, all employees of the company actively responded to the risks and challenges in operation, forged ahead, continued to reform, accelerated the research and development progress of new materials, new processes and new products, and actively expanded new pipelines to adapt to the new normal of epidemic and centralized procurement.

　　

　　II. Description of the company’s main business, business model, industry and R&D during the reporting period.

　　(a) the main business, main products or services.

　　The company is a leading orthopedic medical device manufacturer in China, and its main business is the research and development, production and sales of implantable orthopedic medical devices. The main products are joint prosthesis products and spinal implant products. The company is one of the enterprises with relatively complete medical device registration certificates in the field of joint prosthesis in China, covering four major human joint prosthesis products, namely shoulder, elbow, hip and knee, and spinal implant products are a full range of product combinations of spinal internal fixation systems.

　　(II) Main business models

　　Based on the regulatory laws and regulations of the medical device industry, the national industrial policy, the industry competition pattern, the upstream and downstream development level of the industry, the market operation environment and other factors, and combined with the company’s own development strategic planning, resource factors and technical strength, the company’s business model is determined together.

　　1. Purchasing mode

　　The main procurement contents of the company include three categories: the first category is raw materials, mainly including ceramic blanks, cobalt blanks, titanium blanks, polyethylene and so on; The second category is energy power; The third category serves external processing, mainly including spraying, basic machining and sterilization. The company set up a purchasing department to take charge of the procurement of raw materials and outsourcing services, and formulated a perfect workflow to ensure the efficient operation of the business.

　　(1) Procurement process

　　The purchasing department of the company shall be responsible for making purchasing plans, preparing purchasing orders, transmitting purchasing information, signing purchasing contracts, checking raw and auxiliary materials and establishing purchasing records according to the purchasing needs of various departments.

　　In terms of finished products and raw materials, the company’s procurement process is mainly carried out by bidding. First, the purchasing department conducts pre-qualification and selects three or more qualified units or suppliers to invite bids. Then, the purchasing department and the person in charge of purchasing control the bidding process and select one or more successful bidders for cooperation. The procurement contract drawn up during cooperation should include the necessary clauses such as quality constraint, time constraint and liability for breach of contract. After the contract is approved by the company, sign a purchase contract and quality agreement with the supplier, and ask the supplier to issue relevant certification materials. After the goods arrive, the quality department will control the quality. For outsourcing manufacturers, the company strictly controls the quality of outsourcing products and services by establishing and strictly implementing the selection criteria of outsourcing manufacturers and regularly evaluating outsourcing manufacturers.

　　(2) Development and management of suppliers

　　① supplier access and evaluation mechanism

　　The selection mechanism of suppliers shall be implemented in accordance with the company’s bidding system. Suppliers must have business licenses, legal production and operation certificates, quality management system-related documents, performance and safety evaluation materials of purchased goods, self-inspection reports of enterprises or effective inspection reports issued by qualified inspection institutions. Subsequently, the purchasing department took the lead in organizing the production department, R&D department and quality department to jointly invite tenders, and the suppliers who passed the evaluation were included in the List of Qualified Suppliers, which took effect after being approved by the management of the company.

　　② Quality control measures for suppliers’ supply.

　　The company agreed on matters related to quality compensation in the contract and signed a Quality Agreement with the supplier, binding the quality responsibilities of both parties. If the product is unqualified due to the supplier’s reasons, the supplier shall compensate the buyer for the losses according to the agreement. The company conducts normalized quality communication with suppliers to find out the reasons for unqualified raw materials and ask suppliers to make improvements. After the supplier improvement is completed, the company will check the effectiveness of the improvement, and the company will terminate the cooperation relationship with the supplier who fails to improve as required. The company conducts regular on-site inspections or temporary spot checks on major suppliers, inspects the supplier’s production process, ex-factory inspection process, personnel and equipment and corresponding process records, and judges whether the supplier has quality management capabilities, thus ensuring the quality of supply.

　　③ Settlement mode and settlement cycle

　　The company checks with suppliers every month, and after checking with the system, sorts out different types of business payment documents, which are approved by department managers and company leaders and then transferred to financial personnel for review and remittance.

　　The company settles accounts according to the payment time agreed in the contract, and suppliers with long-term cooperation and a certain purchase amount have a certain credit line.

　　2. Production mode

　　The company mainly produces based on strategic planning, market demand and annual sales target. With the cooperation of relevant departments, the production department carries out the established production and processing tasks according to the production plan, ensuring the company’s annual supply capacity and ensuring a certain safety inventory.

　　The production department tracks the orders received by the sales department in real time, and makes a production plan according to the sales volume in previous years in combination with the company’s safety inventory standards. After the production plan is determined, the production department issues the production task list according to the planned progress, and then enters the specific production process. After picking materials, the production personnel gradually carry out machining, polishing, lettering, cleaning, aseptic treatment and other links, and finally complete the warehousing. The production department of the company strictly implements the system related to production safety. In addition, the company sends safety personnel to supervise and inspect its work, strictly implements rectification for violations of rules and disciplines, and strengthens on-site management and hidden danger investigation to ensure the elimination of hidden dangers and reduce safety accidents.

　　The company’s main production modes are as follows:

　　For products with many varieties and small and medium batches, the company adopts the unit production management mode. This model has the advantage of high efficiency of assembly line production, and can also adapt to the changes of product variety and quantity quickly. The unitized production management mode is mainly composed of two parts: production unit and management unit, in which the production unit takes products as the center, centralizes the layout of equipment with different functions according to the process flow, and creates hardware conditions for realizing continuous production flow; The management unit carries out a series of management optimization around the planning management, personnel management, material management, equipment management and quality management of the production unit, so as to shorten the product delivery cycle and improve the production efficiency on the premise of ensuring the product quality. Under the unitized production management mode, the equipment, personnel and materials are reasonably allocated, and the production mode of "one person and multiple processes" with the goal of "one flow" in the unit is conducive to shortening the processing time and production change time of products with many varieties and small and medium batches.

　　For products with few varieties and large output, the company adopts multi-product batch production mode. In this mode, most products are designed in standardized modules, and the parts are universal and standardized. Employees have a high degree of division of labor and high proficiency in single process operation; Metal die casting, precision casting, die forging, precision forging and other methods are widely used in the production of blanks, with high precision, small machining allowance and high material utilization rate; The production line mostly adopts special and efficient equipment and process equipment, and repeatedly produces one or several similar products. The production process is mechanized and the production cycle is short.

　　For products with individual special requirements, the company adopts customized production mode. Customized production is based on modular design and standardization of parts. According to the special needs of customers, combined with the application of new materials and flexible manufacturing, it carries out secondary development and reorganizes the product structure and manufacturing process. This model not only meets the demand of customization, but also helps to reduce development costs, improve production efficiency and shorten delivery cycle.

　　In addition, the company introduced automatic production equipment in some production links to further improve production efficiency. For example, the company introduced intelligent grinding and polishing automation equipment to grind and polish the femoral stem, ensuring the accuracy of repeated positioning, while the built-in service information system can monitor the feeding of the moving machinery, and the motion control technology can also optimize the performance of the machine.

　　In addition to the above-mentioned self-production mode, based on the existing production capacity and cost control, the company entrusts some production processes to outsourcing manufacturers with corresponding qualifications or conditions for production, mainly involving product spraying, sterilization, surgical tool processing and so on.

　　3. Sales model

　　During the reporting period, the promotion of the "two-vote system" policy has brought certain changes to the sales model of the company and enterprises in the same industry. Before the implementation of the "two-vote system" policy, most enterprises in the industry mainly used the distribution mode to realize the professional division of R&D, production and terminal sales, that is, the manufacturers of orthopedic medical devices focused on the R&D, production, filing, registration and marketing of various orthopedic implants and instruments and tools, and the professional dealers focused on cooperating with the manufacturers to complete the marketing, terminal channel construction, sales and distribution, follow-up service for end customers, and operation follow-up. After the implementation of the "two-vote system" policy, the traditional distribution model was challenged, and sales service providers began to assume the responsibilities of some traditional distributors. Medical device manufacturers, distributors/distributors and sales service providers participated in the product sales and supporting services.

　　The sales modes of the company’s main products include traditional distribution mode, two-vote distribution mode, distributor mode and direct sales mode. During the reporting period, the company’s sales model was mainly based on the traditional distribution model. With the implementation of the "two-vote system", in recent years, the income of the company’s two-vote distribution model and distributor model has increased year by year.

　　(1) the traditional distribution model

　　During the reporting period, the traditional distribution mode was the main sales mode of the company. The main criteria for the company to select a distributor are that the distributor has the qualification for operating orthopedic products stipulated by the state, and the past financial performance and legal compliance of the distributor need to be investigated by the company’s background and field investigation. Due to the different amount of hospital operations, the company has no uniform minimum absolute sales requirements for dealers, but for dealers in some areas, the company will implement a rebate policy when their sales reach a certain target. The company makes full use of the distributor’s sales network and geographical advantages, constantly tapping potential customers, enhancing the product marketing ability and expanding the market share of products. The dealer agreement period is usually one year and is renewed every year.

　　Under the traditional distribution mode, products are sold to terminal hospitals through traditional distributors. Distributors undertake the responsibilities of channel development and customer maintenance, and provide follow-up service and other technical services including preoperative consultation, cargo transportation and equipment disinfection to end customers. At the same time, the marketing team of the company assists distributors to jointly complete channel development and customer maintenance by providing some technical and professional support. The business process of the company’s traditional distribution model is as follows:

　　Under the traditional distribution mode, the company’s payment system is assessed according to two standards: credit period and credit limit, and the payment is required according to the standard that is given priority. At present, most dealers expire the credit line first. After the credit line expires, the company stops the delivery, and the company will deliver the goods after the dealer makes the payment.

　　During the reporting period, the traditional distribution mode of the company was buyout sales.

　　(2) Two-vote distribution mode

　　Under the two-vote distribution mode, products are sold to terminal hospitals through two-vote distributors. Among them, the two-vote distributor only undertakes the functions of channel development and customer maintenance with the assistance of the company, while the follow-up service and other technical services are undertaken by the sales service provider. The business process of the company’s two-vote distribution model is as follows:

　　(3) Distributor mode

　　Under the distributor mode, the company’s products are sold to terminal hospitals through distributors. In this mode, the distributor does not undertake the promotion service function, while the sales service provider undertakes the follow-up service and other technical services under the two-vote distribution mode, and also carries out channel development and customer maintenance with the assistance of the company. In the process of selecting a sales service provider, the company mainly considers the local end-user resources, past service experience, historical cooperation, service personnel’s ability and other factors. The business process of company distributor mode is as follows:

　　(4) Direct selling mode

　　During the reporting period, the company’s main direct selling customer terminals were major hospitals, and the company had long-term and stable cooperative relations with major direct selling terminal hospitals. In recent years, the company’s high-end products have been listed one after another, and the company has also carried out several direct sales of customization/assembly and standard joints in Beijing and other regions. Under the direct selling mode, the channel development, customer maintenance, follow-up service and other technical services of the company’s products are mainly completed by the company’s self-built marketing team. The price of the company’s products is confirmed according to the winning bid price or the internal filing price of the hospital. The business process of the company’s direct selling mode is as follows:

　　For overseas markets, the company may adopt distribution mode, ODM or OEM mode for sales according to the specific situation.

　　In addition, in order to further introduce magnesium alloy-related orthopedic implant products and expand the market of trauma implant products, the company entered into a cooperation and distribution agreement with SynteixAsiaPTE.LTD in August 2019 to obtain the marketing, promotion and sales rights of related products in China, and agreed to purchase certain minimum purchase quantities of contract products within five years. The contract is valid until December 31, 2024, but up to now, SynteixAsiaPTE.LTD has not obtained the medical device registration certificate of related products in China, so the contract has not been formally implemented.

　　4. R&D mode

　　The company’s R&D work is managed in strict accordance with the review principles of quality standards such as ISO13485 and ISO9001/GB/T19001. The specific process is as follows:

　　(1) Project demonstration and establishment

　　Based on the market research of the company’s R&D center, marketing department and other relevant departments, the company formulates the annual product development project plan. The R&D department formulates the annual product development/improvement work plan in combination with the annual product development project plan, market demand, product characteristics and technical requirements, and assigns the design and development project leader, who further clarifies the project name, project objectives, project significance, brief feasibility analysis and project planning time.

　　(2) Project planning and review

　　Combined with the actual situation of the scheme, the project leader further comprehensively evaluates the feasibility of the project, studies and supplements the product specifications, technical scheme, implementation schedule, main key technologies, risk analysis, etc., and arranges and summarizes the scheme and sends it to the department leaders for review. According to the specific needs, the project leader sets up a project team.

　　(3) Design, development and control

　　The project leader shall control the progress of product development/improvement projects as a whole, complete product development and product design change projects according to the requirements of quality system documents, and ensure the standardization of documents, processes and operations. The units of the design and development folder should at least include design and development project initiation, planning, input, output, verification, confirmation, conversion, etc.

　　In this stage, the project leader prepares the design and development input list, and then organizes relevant departments and personnel to review the design and development input.

　　(4) Verification review and registration inspection

　　The project team conducts mechanical and biomechanical tests according to the test plan, and verifies the products according to the relevant national standards, industry standards or company requirements.

　　After the company’s internal projects have passed the verification and review, the project team will prepare the relevant technical requirements documents for medical device products to be registered according to the specific requirements of relevant regulations, prepare samples for registration inspection, and submit them to the medical testing institutions recognized by National Medical Products Administration for registration inspection in time.

　　(5) Clinical evaluation and research

　　The project team and other relevant departments of the company jointly formulate the clinical evaluation plan, and determine whether the product needs clinical trials according to the product characteristics. For the products listed in the Catalogue of Medical Devices Exempted from Clinical Trials or evaluated by clinical trials and usage data of the same kind of medical devices, the company conducts comparison tests of the same products and compiles relevant clinical evaluation materials according to the relevant requirements of the Technical Guiding Principles for Clinical Evaluation of Medical Devices; For products requiring clinical trials, cooperate with CRO (Contract Research Organization) and other companies to take the lead in completing clinical trial plans and clinical trial summary reports.

　　(6) Application for submission and registration

　　The personnel in charge of registration in the project team shall compile relevant registration materials, register products and obtain approval.

　　(3) the industry situation

　　1. The development stage, basic characteristics and main technical threshold of the industry.

　　A. Industry development stage

　　Orthopedic implant medical devices is one of the important subdivisions of medical devices. Orthopedic implanted medical devices refer to the devices and materials that can be implanted into the human body through surgery to replace and support human bones or repair bones, joints, cartilage and other tissues, mainly including bone joint implants and joint implants, such as bone plates, bone screws, intramedullary nails, spinal fixation implants, artificial joints, etc., which belong to high-value medical consumables. Because they are implanted into the human body for a long time, they have a great impact on human life and health, and their value is usually high. According to the report on punctuation information, it is estimated that the market size of orthopedic implantable medical devices in China will be about 60.7 billion yuan in 2024, and the compound annual growth rate from 2019 to 2024 will be about 14.51%.

　　According to the different parts of use, orthopedic implanted medical devices can be divided into four categories: trauma, spine, joint and others. In China’s orthopedic implantable medical device market in 2019, the market segments of trauma, spine and joint accounted for 85.80% of the market; Among them, trauma is the largest market segment, accounting for 29.80%; Spine ranks second, accounting for 28.23%; Joints ranked third, accounting for 27.77%.

　　(1) Joint implanted medical devices

　　According to different parts, artificial joints can be divided into artificial hips, knees, shoulders, elbow joints and so on. Benefiting from the growing medical demand, the joint market has maintained a rapid growth. According to the punctuation information related reports, the market size of joint implanted devices in China in 2018 and 2019 is 7 billion yuan and 8.6 billion yuan respectively. It is estimated that the market size of joint implanted medical devices in China will be about 18.7 billion yuan in 2024, with an average annual compound growth rate of about 6.87% from 2019 to 2024. Due to the relatively high technical difficulty, complex production process and long service life of joint implants, the market for joint implants is mainly imported products, while domestic products account for a relatively low proportion.

　　(2) Spinal implants.

　　Benefiting from the increasing medical demand and the development of minimally invasive spine technology, the market scale of spinal implant medical devices in China is also growing gradually. According to the report on punctuation information, the market size of spine medical devices in China is 7.3 billion yuan and 8.7 billion yuan in 2018 and 2019 respectively. It is estimated that the market size of spine medical devices in China will be about 17.1 billion yuan in 2024, and the compound annual growth rate from 2019 to 2024 will be about 14.42%.

　　(3) Implanted medical devices for trauma.

　　The production technology of trauma products is mature and the market development is sufficient, which has maintained rapid growth in recent years. According to the report on punctuation information, the market size of trauma implanted devices in China was 7.7 billion yuan and 9.2 billion yuan in 2018 and 2019 respectively. It is estimated that the market size of trauma implanted medical devices in China will be about 17 billion yuan in 2024, and the compound annual growth rate from 2019 to 2024 will be about 13.15%.

　　(1) International medical device giants have more advantages in the market.

　　Although the overall gap between domestic medical device companies and international medical device giants is narrowing year by year, the problem of low overall level of medical device companies in China still needs to be solved. In the domestic and international markets, international medical giants still occupy the dominant position by virtue of strong technical strength, R&D ability, capital supply ability, brand influence and higher trust.

　　With the acceleration of import substitution, the market share of domestic enterprises has gradually increased. However, from the perspective of the market segmentation of orthopedic implants, the degree of localization of the joint market is still low, and at present, imported enterprises still occupy a dominant position.

　　(2) The industrial concentration of Class 2)III medical device enterprises has gradually increased.

　　Under the leadership of international medical device giants, domestic medical device companies, on the one hand, step up their technological catch-up and constantly narrow the gap with international giants, on the other hand, accept increasingly strict government supervision, while the fierce competition among companies continues to increase, and high-quality enterprises rise, making it difficult for some small and medium-sized enterprises to continue to operate and be eliminated. Generally speaking, the industry concentration of Class III medical device enterprises with high technology content is gradually increasing, and the trend of survival of the fittest, mergers and acquisitions is obvious. According to the Statistical Annual Report on Drug Supervision in National Medical Products Administration, by the end of November 2018, there were only 1,997 enterprises that could produce three types of products, which was 25.37% lower than the 2,676 enterprises at the end of 2013. With the backward small and medium-sized enterprises being gradually eliminated or merged, the concentration of China’s medical device industry will continue to rise, and the scale of enterprises will gradually expand. While broadening the product line, they will continue to consolidate and expand their own advantages.

　　(3) Domestic medical device companies are accelerating the process of import substitution.

　　Due to the lack of strict and unified standards for equipment industry and the influence of municipal/hospital bidding mode, the medical equipment industry has been in a state of low concentration. Therefore, for a long time, many medical device companies developed in specific areas by relying on their special geographical location and marketing network. However, with the improvement of domestic innovation ability and technical level, the scale of domestic medical device companies continues to expand, R&D investment continues to increase, and the quality and approval number of domestic devices have improved, which provides the possibility for domestic products to occupy more market share.

　　In addition, hospitals at all levels have certain pressure to control medical insurance fees, especially the basic medical insurance system for urban residents, whose fees are mostly divided by age, and the overall amount is small; In terms of reimbursement amount, the reimbursement amount for urban residents is limited. Therefore, the long-term pressure of medical insurance fee control is great, and the increase in the use of domestic devices is an inevitable trend, which also provides an opportunity for domestic companies to accelerate import substitution.

　　(4) The development history is short and there are few large-scale enterprises.

　　The development history of domestic medical high-value consumables industry is only more than 20 years. In the field of orthopedics, the domestic manufacturers of orthopedic medical devices have a certain production capacity, and their products can basically cover various types of orthopedic diseases, and they have made certain progress in the fields of joint reconstruction devices, trauma and fixation orthopedic medical devices, orthopedic surgical instruments and spinal fixation devices. However, most domestic manufacturers of orthopedic implant consumables are small in scale, and their core products and market dominance are limited.

　　At present, there are few manufacturers of orthopedic implant consumables in China. From the perspective of enterprise scale, China’s orthopedic industry is still in a relatively primary stage. At the same time, because there is still a gap with imported products in prosthesis materials, prosthesis shape design, accuracy of surgical positioning instruments, joint surface smoothness, and treatment of contact surface with bone, the products of domestic manufacturers mainly focus on trauma and spine products, and the share of state-owned manufacturers in the joint market is relatively low.

　　(5) The competition pattern is scattered, and the trend of industry integration is obvious.

　　Because most of the manufacturers of high-value medical consumables and orthopedic implants in China are small in scale, the industry competition pattern is relatively scattered. In recent years, major market participants have integrated through mergers and acquisitions. For example, in 2012, Johnson & Johnson acquired Synthes, a Swiss medical plastic equipment manufacturer, and later joined DePuy subsidiary to become Johnson & Johnson DepuySynthes；; Stryker acquired China Enterprise Chuangsheng Medical in 2013; Medtronic acquired Kang Hui Medical in 2012; Xerox has successively acquired American sports medicine product manufacturer ArthroCareCorp, orthopedic robot company BueBet, and the BST-CarGe cartilage repair business of Indian pharmaceutical company PiramaHeathcare. The trend of industry integration is obvious, which provides development opportunities for enterprises with considerable scale in the industry. According to the report on punctuation information, in 2019, the top five companies in China’s orthopedic implantable medical devices market were Johnson & Johnson, Medtronic, Jiemai, Stryker and Weigao Orthopedics, with market shares of 17.24%, 9.70%, 5.97%, 5.19% and 4.61% respectively, totaling 42.71%, and the industry concentration increased.

　　(6) The demand for high-end products is still expanding.

　　With the increase of national disposable income, the increase of the proportion of the elderly population, the change of medical concept and the expansion of medical insurance coverage, the demand for high-end orthopedic medical devices in China will maintain a high growth rate.

　　After years of market cultivation, patients’ acceptance of orthopedic implants has been continuously improved. In the future, investment and mergers and acquisitions in the field of high-end orthopedic medical devices will increase, and good market prospects and huge growth space will bring greater impetus to the development of enterprises.

　　C. Main technical thresholds

　　Medical devices are knowledge-intensive and technology-intensive industries with multidisciplinary integration, and because orthopedic medical devices are directly applied to the human body, the safety, effectiveness, accuracy and reliability of medical device products must be guaranteed, which means that medical device manufacturers must continuously improve their technical level through continuous research and statistical analysis of large-scale clinical data before they can develop products that guarantee quality and meet customer needs. New entrants to the industry often do not have this technical level, and the difficulty of entering the market is further increased.

　　2. Analysis of the industry position of the company and its changes.

　　Based on China’s huge population base and the trend of accelerating aging, China’s orthopedic market is huge and has considerable growth potential. International orthopedic giants have successively entered the China market through local mergers and acquisitions or investment in factories. The period of investment and factory building is longer than that of mergers and acquisitions. Most international orthopedic giants choose mergers and acquisitions to open the China market.

　　In recent years, with the support of national policies and the opportunity of domestic market expansion, domestic orthopedic medical science and technology companies have gradually developed and expanded. The main domestic listed companies in the same industry mainly include Aikang Medical, (), Weigao Orthopaedics, () and Sanyou Medical.

　　The company’s main products are joint implant consumables. Because the artificial joint prosthesis needs to form a permanent combination with human bone tissue and replace the original function of human body, the raw materials of artificial joint must have better compatibility with bone and advanced bone interface fixation technology, which has higher manufacturing threshold and technical difficulty. Therefore, artificial joint is an orthopedic subdivision field with high technology content, high added value and high entry threshold. Due to the limitation of domestic raw materials and technology, imported enterprises still occupy the absolute dominant position in the whole market segment.

　　According to the report on punctuation information, in 2017, 2018 and 2019, the market share of foreign-funded enterprises in the joint implant device market in China was 67.88%, 66.71% and 65.06% respectively. The market share of local enterprises is 32.12%, 33.29% and 34.94% respectively, and the proportion is increasing year by year. Among them, Chunli Medical occupied 8.96% of the market share of joint implanted medical devices in China in 2019, ranking second among all local enterprises and fourth among all joint prosthesis enterprises (including foreign enterprises) in China.

　　3. The development of new technologies, (), new formats and new models during the reporting period and the future development trend.

　　3D printing technology: The company has introduced a variety of 3D printing equipment with different process types, and the "research and development project of customized and personalized prosthesis series products" is also in progress.

　　The company’s 3D printing equipment mainly includes EBM (Electron Beam Melting) equipment, MJF (Multi-jet Melting) equipment, and powder metal 3D printing equipment. Among them, electron beam molten metal 3D printer can melt titanium alloy powder layer by layer by using electron beam in vacuum to generate dense parts, which can realize printing of porous materials. Chunli Medical has mastered the technology of using electron beam technology to produce bone trabecula and other products. Multi-jet melting 3D printer ensures the fineness of the edge of the printed object by spraying solvent and fine agent to the laid powder, and then carries out thermal radiation heating again, so that the powder is bonded according to the model interface and stacked layer by layer.

　　Chunli Medical has mastered the technology of using multi-jet melting 3D printer to produce guide plate, prosthesis die test and other instrument parts. In addition, Chunli Medical can use the powder-feeding metal 3D printer to coat the surface of the medical implant produced by the traditional technology with the metal powder of medical institutions. The metal powder is uniformly melted by laser irradiation, and then cooled into a solid to be combined with the metal surface, so as to realize the porous structure on the surface of the implant and promote bone growth. In recent years,

　　Chunli Medical is developing a product called Advanced Customization and Individualized Joint Prosthesis based on advanced technologies such as China National Bone Database and 3D Reconstruction. Compared with the existing customized joint prosthesis products, Chunli Medical can more effectively analyze and meet the specific needs of patients. In addition, in August, 2020, Chunli Medical was hired as the drafting unit of the Group Standardization Technical Committee of the 3D Printing Medical Device Professional Committee of China Medical Device Industry Association, and participated in the formulation of the group standards of 3D Printing Tantalum Metal Hip Prosthesis, 3D Printing Tantalum Metal Knee Prosthesis, 3D Printing Tantalum Metal Personalized Bone Defect Filler and 3D Printing Tantalum Metal Spinal Prosthesis, and was rated as the "Advanced Drafting Unit of the Group Standard of 3D Printing Medical Devices" by the professional committee.

　　New material technology: the company has carried out research and development on porous tantalum materials and magnesium materials. Compared with other prosthetic materials, porous tantalum has a unique bone-like structure, high porosity is conducive to bone growth, highly interconnected honeycomb structure provides extensive bone growth, high friction coefficient provides good initial stability of the implant, and its physical and mechanical properties are close to that of bone, so it is an ideal bone substitute material. The project "Development and Clinical Application of Porous Tantalum Bone Repair Materials and Implantable Products" declared by the company was approved by the Ministry of Science and Technology as the key project of the National Key R&D Plan "Research and Development of Biomedical Materials and Repair and Replacement of Tissues and Organs" in 2020. In the "Tantalum Technology Series Product R&D Project", the company plans to prepare porous tantalum by CVD (Chemical Vapor Deposition) and produce customized porous tantalum personalized bone defect filler. At present, it has obtained the acceptance notice of medical device registration application issued by National Medical Products Administration; In the "research and development project of dental series products", the company plans to design customized and individualized dental implant products with porous tantalum and complete the production conversion, which is currently in the design and inspection stage.

　　Biomedical magnesium alloy, as a representative of a new generation of biodegradable biomedical materials, has received extensive attention in recent years. At present, the listed products are mainly concentrated in foreign countries, and the indications are narrow. Compared with other medical metal materials, magnesium alloy has obvious advantages, such as good biodegradability, biological safety and biomechanical compatibility. The mechanical properties are similar to those of bone tissue, which can be degraded after being implanted in the body, avoiding the second operation to take out instruments, which is beneficial to revision surgery and reducing the economic burden and mental stress of patients. At present, the company’s "research and development of new biomedical materials series products" project is in the design stage.

　　To sum up, the company has made great efforts to research and develop related emerging technologies as innovative application directions, and the research and development work is progressing in an orderly manner.

　　(IV) Core technologies and R&D progress

　　1. Core technologies and their advanced features and changes during the reporting period.

　　The company has been focusing on the research and development, production and sales of implantable orthopedic medical devices. After years of research and development, the company has mastered a number of core technologies, including general upgrade technology and unique technology. Among them, universal upgrade technology is a technology based on universal technology or necessary technology, combined with Chinese bone characteristics, clinical needs and feedback, to optimize and upgrade product performance or technology; Unique technology is the core technology realized by the company based on R&D experience and future R&D planning through continuous research and development by relevant personnel. The core technologies mastered by the company include hip joint core technology, knee joint core technology, shoulder and elbow joint core technology, joint bone defect technology and spine core technology.

　　The details of the company’s main core technologies are as follows:

　　(1) Core technology of hip joint

　　The core technologies of hip joint mainly include low-friction joint interface technology, personalized biological femur technology, press-fit biological acetabulum technology and hip joint revision prosthesis filling technology.

　　Advanced technology of low-friction joint interface: ① Low-friction joint interface technology refers to the technology of improving the reliability and stability of ceramic parts and reducing the risk of broken ceramic parts by optimizing the processing technology of mortar cups and lining used with ceramics, thus prolonging the service life of artificial joints. ② During hip replacement, the straightness and roundness of products used with ceramic components should be strictly controlled, so as to avoid the uneven installation stress of ceramic components during clinical use and assembly, which will lead to the fragmentation of ceramic components. ③ At present, the machining tolerance of acetabular cup and polyethylene liner of most manufacturers in the market is difficult to meet the precision requirements of ceramic assembly. The machining accuracy of the straightness and roundness of the locking structure of ceramic liner and acetabular cup of our company is controlled at 0.007mm, and the machining error in the product processing process is controlled through special tooling and fixtures to ensure stability and consistency, prevent the ceramic components from being broken due to installation deformation during use, and at the same time, the more reliable locking mechanism enhances the anti-dropping ability of the prosthesis. ④ As far as ceramic materials are concerned, foreign giants and major domestic enterprises all adopt CeramTecGmbH bioceramic materials; As far as processing technology is concerned, the company is reliable in straightness and roundness, and there is no obvious gap between the company and the highest level in the industry.

　　Advance of personalized bio-femoral technology: ① Personalized bio-femoral technology refers to the technology of optimizing the neck length, eccentricity, proximal and distal dimensions of femoral prosthesis based on the basic data of Chinese physiology and anatomy, and cooperating with the tools corresponding to the press-fit relationship to obtain better medullary cavity matching, stability and anti-rotation performance. ② Based on the basic data of the bones around the hip joint in China collected in the "Chinese Bone Mapping Project", combined with this technology, a personalized biological femoral prosthesis suitable for the physiological anatomical structure of Chinese people is designed, which includes two neck shaft angles of 127 and 133, and each neck shaft angle is divided into two eccentric distances, with an interval of 0.5mm as a specification; There are 4 models and 100 specifications, and the size interval between adjacent specifications is small, which is highly matched with the patient’s medullary cavity. At the same time, the prosthesis has medial and lateral grooves designed based on the different load properties between the proximal bone and the prosthesis, which effectively improves the initial stability and anti-rotation performance of the prosthesis. The optimized lateral shoulder design of this kind of prosthesis can also be applied to minimally invasive surgery.

　　The advance of that press-fit biological acetabulum technology: ① the press-fit biological acetabulum technology refers to improve and optimizing the acetabulum design, so that the "equator" position of the acetabulum cup is stressed, the force transmission mode is optimized, and bet stability, component connection reliability, wear resistance and the like are obtained. ② The press-fit biological acetabular prosthesis designed in combination with this technology includes a acetabular cup and a acetabular lining. The outer surface of the acetabular cup is composed of a spherical cap, a hollow spherical table in the middle and a hollow spherical table at the bottom in turn, and its total height is lower than the bottom radius of the hollow spherical table at the bottom. When the prosthesis is installed, this design makes the "equator" position of the cup bear force, optimizes the transmission mode of force, and increases the initial and long-term stability of the prosthesis. The connection mode between the inner liner and the outer cup is taper press-fitting and slot locking, and the plum blossom anti-rotation design increases the connection reliability between the parts and enhances the stability between the two parts. And the service life and wear resistance of the prosthesis are improved. This technology can realize the universal matching between mortar cup and ceramic or polyethylene lining, which is convenient for clinical use.

　　Advanced filling technology of hip revision prosthesis: ① The filling technology of hip revision prosthesis refers to the technology of optimizing the filling design of acetabulum defect, making the shape and internal structure of the filler more suitable for the growth of cancellous bone and improving the compatibility between the filler and acetabulum. ② The prosthetic fillers for hip joint revision designed by this technology include crescent, L, round and other forms. The overall mesh structure design of the prosthesis forms a honeycomb structure with internal interconnection, and the pore size of its porous structure can reach 500 200 μ m; The diameter of porous structure of trabecular bone can reach 500 200 μ m; The porosity of trabecular bone porous structure is 50~80%, which can make cancellous bone grow into prosthesis quickly and firmly, and the elastic modulus of prosthesis is close to the physiological bone level of human body. After the implant of prosthesis filler using this technology, it conforms to the physiological stress distribution, reduces stress shielding to a greater extent and promotes bone growth; Moreover, the filler can be compatible with the total hip socket and used in combination, which is suitable for cases with acetabular defects of different degrees and meets the clinical needs of patients. (3) Influenced by technological conditions, the related parameters of acetabular reinforcement, such as aperture, wire diameter and porosity, affect the bone ingrowth effect. Compared with similar products in the current market, the company’s hip joint revision prosthesis filler meets the requirements of relevant national and industry standards, and its porous characteristics can better meet the conditions of bone growth, and its specifications and models are richer, which is conducive to meeting the needs of patients with different degrees of illness.

　　(2) Core technology of knee joint

　　The core technology of knee joint mainly includes high polishing anatomical tibial platform technology, optimized femoral condyle anterior condyle and patella pulley technology, semi-open femoral condyle intercondylar fossa technology and diversified platform pad technology.

　　Advanced technology of high polishing anatomical tibial platform: ① High polishing anatomical tibial platform technology refers to the technology of improving and optimizing the design of tibial platform and adopting high polishing in the internal groove of tibial platform support, which can reduce the wear between the platform pad and tibial platform support and prolong the service life of prosthesis. ② Based on the basic data of the bones around the knee joint in China collected in the "Chinese Bone Mapping Project", the anatomical tibial plateau designed with this technology has better coverage of the tibial osteotomy surface, which effectively reduces the risk of tibial plateau sinking; On the basis of the original locking mechanism, the central anti-rotation island structure is added to further reduce the fretting between the pad and the tibial tray, reduce the back wear of the pad and reduce the osteolysis; The double-wing design can not only increase the mechanical strength but also improve the anti-rotation stability of the prosthesis.

　　Advanced technology of optimized femoral condyle anterior condyle and patella pulley: ① The optimized femoral condyle anterior condyle and patella pulley technology means that by improving the design of femoral condyle, the femoral condyle anterior condyle of knee joint is thinned, and the left and right sides adopt arc design technology, which can reduce the friction of anterior patellar muscle ligament, reduce the pressure and wear of contact surface, and effectively avoid anterior patellar pain. ② The optimized design of patella pulley can extend, deepen and lengthen the patella pulley in the whole range of motion, which is helpful for the patella to enter the patella pulley as early as possible, and makes the patient less prone to patella dislocation, snapping and pain after operation.

　　Advanced technology of semi-open femoral condylar intercondylar fossa: ① semi-open femoral condylar intercondylar fossa technology refers to the technology of optimizing the design of intercondylar fossa, reducing the amount of bone cutting, achieving the purpose of bone preservation and reducing wear. ② The femoral condyle designed by this technology adopts semi-open intercondylar fossa design, which solves the problem of large intercondylar bone cutting and preserves the intercondylar bone mass to the greatest extent; At the same time, the intercondylar box structure adopts high polishing design, which can reduce the wear of the platform pad column to the greatest extent.

　　Advanced technology of diversified platform pad: ① By optimizing the design of knee platform pad, diversified platform pad technology can meet the needs of different patients while achieving better stability and reducing wear. ② The products designed with this technology include the platform pad without cruciate ligament and the platform pad with cruciate ligament. Among them, the platform pad without cruciate ligament is designed with aquiline nose, which effectively prevents the risk of dislocation during high flexion; A double joint surface combination is formed between the column and the cross beam, which reduces the pressure of the cross beam on the column and reduces the wear; When buckling, the contact surface between the beam and the column gradually moves down from top to bottom, and when the buckling degree is large, the beam contacts the bottom of the column; Reduce the impact force and effectively prevent the column from breaking. However, the gasket of CR-type platform pad with backward inclination of 3 degrees is suitable for patients with intact posterior cruciate ligament and bilateral collateral ligaments. CR deep disc table pad is designed with 0 back inclination angle and raised back lip of pad, which is suitable for patients with functional problems of posterior cruciate ligament and bilateral collateral ligaments.

　　(3) Core technology of shoulder and elbow joint

　　The core technology of shoulder and elbow joint mainly includes proximal humeral prosthesis design technology and distal humeral prosthesis design technology.

　　Advanced design technology of proximal humeral prosthesis: ① Anatomical humeral stem technology refers to the technology of improving the anti-rotation performance of prosthesis and prolonging the life of prosthesis by optimizing the shape of humeral stem of shoulder joint, the structural design and combination of osteotomy surface. ② During shoulder joint replacement, the fretting and rotation of the humeral stem can easily lead to osteolysis and the sinking of the humeral stem, which will affect the service life of the prosthesis. Combined with this technology, the design of the proximal ellipse of the shoulder joint prosthesis can effectively prevent the fretting caused by prosthesis implantation and avoid osteolysis. The disc design at the top of the prosthesis will cover the osteotomy surface after the prosthesis is implanted to prevent the prosthesis from sinking in the later stage; To some extent, it can prolong the service life of artificial joint, reduce the revision rate and relieve the pain of patients.

　　Advanced design technology of distal humerus prosthesis: ① Anatomical distal humerus technology refers to the technology of optimizing the shape and width of the lower humerus, reducing unnecessary bone cutting and ensuring postoperative bone integrity. ② In elbow replacement, when the humerus side is treated, the two sides of the treated humerus lower end are easy to break, which affects the stability of the prosthesis. The elbow humerus handle designed by combining this technology can effectively ensure the stability of the prosthesis after installation, and at the same time, reducing the width can adapt to more patients and improve the application range of the prosthesis.

　　(4) Repair technology of articular bone defect.

　　Joint bone defect repair technology mainly includes pelvic bone defect repair technology, knee joint bone defect repair technology and customized individualized bone defect repair technology.

　　Advanced pelvic bone defect repair technology: ① The pelvic bone defect repair technology is suitable for severe comminuted fracture of acetabulum, revision of acetabulum with a large number of bone defects, severe pelvic bone defects caused by pelvic tumors, etc. The pelvic prosthesis can better achieve limb preservation, and on this basis, it can realize the integration of prosthesis, bone and muscle in the state of severe pelvic bone defect. ② The acetabular prosthesis designed with this technology can be fused with acetabular bone in patients, and the acetabular prosthesis is more firmly fixed; The range of acetabular motion angle is large, which prevents acetabular prosthesis dislocation; The acetabular prosthesis can be assembled at will according to the conditions of different patients, which meets the needs of acetabular prosthesis of different patients; Can save limbs for patients and meet different osteotomy positions in hip and acetabular surgery, the acetabular prosthesis is consistent with the position and angle of the acetabulum in the original patient, and the function of the human body can be effectively and reliably reconstructed; The iliac buttress is provided with nail holes, so that the prosthesis can be firmly fixed with human bones, and the bone contact surface is of trabecular structure, which promotes human bones to grow into the pores, and further improves the firmness.

　　Advanced technology of knee joint bone defect repair: ① Through optimizing the product design, knee joint bone defect repair technology can restore the flexion and extension, internal and external rotation functions of knee joint under the condition of a large number of bone defects, and fully meet the activity needs of patients on the premise of limb preservation. ② The knee prosthesis designed with this technology is composed of femoral condyle, tibial plateau support, femoral marrow needle, tibial marrow needle, osteotomy section, etc. The convex articular surface of femur is in direct contact with the concave articular surface of tibia, which increases the contact surface of the joint and restores the flexion and extension and internal and external rotation functions of the knee joint. One end of the restraint is connected with the femur with a transverse shaft, and the other end of the restraint is directly inserted into the central hole of tibia to make the prosthesis achieve maximum stability. Bionic modeling is adopted to fully meet the requirements of patients’ activities on the premise of limb preservation, so that patients can recover as freely as before.

　　The advance of customized and individualized bone defect repair technology: ① customized and individualized bone defect repair technology can customize the joint prosthesis by using advanced digital processing technology to better meet the special needs of patients. ② The development of customized and individualized artificial joints makes up for the shortcomings in the field of artificial joints, so that patients with rare and difficult bone diseases can obtain unique personalized prostheses. Combined with this technology, the joint prosthesis designed can be customized through the reverse use of three-dimensional data, which can solve the problem that special diseases need special-shaped structures and complex structures. Taking clinical application as the cornerstone, it integrates clinical, mechanical design, materials, technology, machining and other multidisciplinary advanced technical means to achieve the purpose of mutual supplement and mutual promotion between individualized prosthesis and standard joint.

　　(5) Core technology of spine

　　The core techniques of spine mainly include posterior cervical nail plate fixation technique, omni-directional large angle screw technique and anterior cervical fixation technique.

　　The advance of cervical posterior screw-plate fixation technology: ① cervical posterior screw-plate fixation technology refers to that technology of optimize the structure of the fixation plate, which can not only play a supporting role, but also fuse the bones, thus avoiding the re-closing of the door after the posterior laminectomy. ② The products designed with this technology mainly include fixing plates and screws. Among them, a porous three-dimensional structure is formed on the inner side of the fixation plate opposite to the cervical vertebrae, which can induce the bone to grow in, so that the posterior cervical nail plate fixation device and the lamina are fused together, which is beneficial to the support and fusion of the lamina and solves the problem of closing the door after operation.

　　Advanced technology of omni-directional large-angle screw: ① omni-directional large-angle screw technology refers to the technology of improving the movable angle of screw to facilitate surgical implantation by optimizing the screw structure. ② The products designed in combination with this technology mainly include nail sleeves, fasteners, washers, locking nails, plugs, etc. Pedicle screws can obtain a unilateral swing angle of 50 degrees, which makes the implantation of connecting rods more convenient and flexible, and meets the needs of alignment of most doctors in clinical surgery and anatomical variation fixation.

　　Advance of anterior cervical fixation technology: ① Anterior cervical fixation technology refers to the technology of reducing the notch of anterior cervical bone plate by optimizing the structure of bone plate and locking ring, and reducing the swallowing difficulty of patients due to too high notch. ② The products designed with this technology mainly include bone plates and screws. Screw holes are formed in the bone plates, and screws can be implanted into the screw holes in the bone plates to connect the bone plates with vertebral bodies. Locking rings are embedded in the screw holes in the bone plates. After the screws are implanted into the screw holes in the bone plates, the locking rings contact with the nut positions of the screws and expand to lock the screws in the screw holes in the bone plates. The original locking nail is changed into the current screw self-locking structure, which reduces the risk of screw falling off, and adds positioning holes on the bone plate to prevent the bone plate from shifting when implanted.

　　During the reporting period, none of the above core technologies has changed.

　　2. R&D achievements obtained during the reporting period

　　As of December 31st, 2021, the company held 49 registration certificates and filing vouchers for producing medical devices (joint prosthesis products, spine products and sports medical products covering our four joints) in China, among which 16 were Class III medical device registration certificates, 4 were Class II medical device registration certificates and 29 were Class I medical device filing vouchers.

　　In terms of domestic registration, the company obtained the registration certificate of single condyle knee joint and patellofemoral joint prosthesis. In terms of international registration certificate, the company has obtained the CE certificate of expanded hip joint prosthesis, CE certificate of expanded knee joint prosthesis, EU free sales certificate of hip joint prosthesis and EU free sales certificate of knee joint prosthesis, and obtained the registration certificates of hip joint prosthesis, knee joint prosthesis and spine prosthesis in Syria, Iraq and Ecuador, the registration certificates of hip joint prosthesis and knee joint prosthesis in Turkey and the registration certificates of tumor hip joint prosthesis and tumor knee joint prosthesis in Mexico.

　　The company has obtained the transformation project of scientific and technological achievements in Tongzhou District, Beijing, the transformation project of tantalum modified biomedical titanium alloy materials, the industrialization project of patented technological achievements in Tongzhou District, the key support project of high-tech industry development in Tongzhou District in 2021, the registration certificate of spinal fusion cage and hip prosthesis, the key support project of high-tech industry development in Tongzhou District in 2022, the digital workshop construction project of orthopedic implants, and the research of porous tantalum artificial vertebral body in Beijing’s innovative studio project of outstanding young engineers. Company Post-Doctoral Research Center obtained the general project of China postdoctoral science fund "Study on Composite Modification of Ceramic Surface of Medical Zirconium Alloy and Its Service Performance", the project funded by Beijing postdoctoral research activities "Design of Multi-layer Membrane Structure and Study on Friction and Wear Behavior of Tantalum Modified Biomedical Titanium Alloy Surface" and the open project of State Key Laboratory "Preparation Technology and Performance Study of In-situ Oxidized Ceramic Layer on Biomedical Zirconium Alloy Surface".

　　A number of products developed by the company have obtained Beijing new product and new technology certificates, including 160 femoral stem (certificate number:

　　3. R&D investment table

　　Reasons for significant changes in total R&D investment compared with the previous year

　　Mainly because the company attaches importance to the research and development of new products, new technologies and new processes, and continues to increase the demonstration of R&D projects, the investment in R&D personnel salaries and other related expenses has increased; Based on the national joint collection situation, the company has increased the research and development of new pipelines such as joint surgery robot, sports medicine, PRP and oral cavity.

　　4. Research projects

　　5. R&D personnel

　　6. Other explanations

　　

　　Iii. Analysis of core competitiveness during the reporting period

　　(A) analysis of core competitiveness

　　During the reporting period, the company’s core competitiveness has not changed significantly.

　　1. Technical barriers to product design

　　① Implants with appropriate size, shape and design can significantly increase the success rate of orthopedic surgery, among which the main performance of joint products is to require its wear resistance and stability of bone interface, so as to prolong the service life of products. Among them, the improvement of wear performance is realized by the selection of friction materials and the design of joint construction, and the stability of bone interface is realized by surface treatment technology and the design of handle, cup and other parts. ② As one of the earliest enterprises in China to develop and produce advanced joint prosthesis products, based on clinical needs and doctors’ suggestions, the company has continuously improved its technical level through continuous research and statistical analysis of large-scale clinical data, and mastered mature experience in product design and development, from product market research, project establishment, drawing design and parametric programming, to product finite element analysis, mechanical test, biological or zoological verification, clinical trial, product functional test, and then to registration application and trial production.

　　2. Technical barriers to product processing

　　① The production and processing of orthopedic implanted medical devices involves many processes, such as blank forming, machining, surface treatment, laser marking, cleaning, sterilization and so on, which requires high quality and safety of products. ② The company has a relatively mature and perfect processing flow, with traditional materials-reducing processing equipment such as turning, milling, planing, grinding and drilling, and materials-increasing processing equipment such as metal printers and resin printers, so as to ensure that the processed products are qualified in all aspects and accurately control every link in the production process. ③ The company has mastered some new processing technologies. The mesh structure of 3D printing products can realize rapid and firm bone growth. The company has advanced 3D printing equipment and mastered more mature printing technology, which can print biological prostheses with excellent performance. In addition, the company has initially mastered the chemical vapor deposition (CVD) process, which can realize the production of some porous tantalum metal products.

　　3. Technical barriers to research and development of new materials

　　① Biomedical degradable magnesium and magnesium alloy products: Biomedical magnesium alloy, as a representative of a new generation of biodegradable biomedical materials, has received extensive attention in recent years. At present, the company’s research based on magnesium alloy is being carried out in an orderly manner. ② Porous tantalum: Compared with other prosthetic materials, porous tantalum metal products have a unique structure similar to bone, high porosity contributes to bone growth, highly interconnected honeycomb structure provides extensive bone growth, high friction coefficient provides good initial stability of implants, and its physical and mechanical properties are close to those of bones, so it is an ideal bone substitute material; At present, the company’s research based on porous tantalum is being carried out in an orderly manner. The project "Development and Clinical Application of Porous Tantalum Bone Repair Materials and Implantable Products" led by the company was approved by the Ministry of Science and Technology as the key project of the national key R&D plan "Biomedical Materials R&D and Tissue Organ Repair and Replacement" in 2020.

　　(II) Events that have seriously affected the core competitiveness of the company during the reporting period, impact analysis and countermeasures.

　　

　　Fourth, risk factors

　　(A) Not yet profitable risk

　　(2) Risk of sharp decline in performance or loss

　　(C) core competitiveness risks

　　Orthopedic implanted medical devices stay in the human body for a long time, which requires high safety and needs to conform to the human bone structure. On the one hand, the ideal orthopedic implant material needs to have good biological properties such as biocompatibility, bioactivity and corrosion resistance, on the other hand, it needs to have good mechanical properties such as fatigue strength, mechanical stability, friction and wear performance. In recent years, new materials such as PEEK, degradable magnesium alloy and bioceramics have also appeared in clinical applications. The company has made corresponding layout for the research and development of new materials such as porous tantalum, magnesium alloy and PEEK, but there is still a certain gap compared with foreign giants. In the process of R&D, on the one hand, the company may face risks such as deviation in its own R&D direction, lagging R&D progress, and unsatisfactory R&D results, which may lead to an increase in R&D costs and time investment or even the suspension or failure of R&D projects; On the other hand, if the company’s R&D fails to achieve the expected material results and turn them into products, or the new materials cannot be effectively industrialized due to factors such as production technology and production cost, or the new materials cannot be successfully recognized by customers and markets, the company’s early R&D investment may not bring the company income or enhance its competitive advantage as expected, thus adversely affecting the company’s ability to continue to operate.

　　(4) Operational risks

　　(A) the risk of changes in sales model

　　The sales modes of the company’s main products include traditional distribution mode, two-vote distribution mode, distributor mode and direct sales mode. During the reporting period, the company’s sales model was mainly traditional distribution model. With the continuous expansion of the promotion scope of policies such as "two-vote system" and "purchasing with quantity", the revenue proportion of the company’s traditional distribution model will decrease year by year in the future. If the company can’t adapt to the changes of sales model in time and enhance the transformation ability of sales model, it will face the risk of blocked sales channels and customer loss.

　　(B) Market competition intensifies risks

　　The company’s main products are implantable orthopedic medical devices, and its end customers are medical institutions. For a long time, most of the domestic market share has been occupied by international brands such as Johnson & Johnson, Medtronic and Stryker. In recent years, with the technical progress and policy support, the trend of localization substitution is obvious.

　　However, the market share of domestic brands is still small, and domestic brands are facing fierce competition. The company must improve its product innovation and R&D strength according to market changes and industry development trends, so as to maintain its competitive advantage and develop steadily in the rapidly changing market environment. If the company fails to accurately grasp the development trend of the industry or correctly respond to the sudden changes in market competition in the future, it will face the risk of declining market share and product prices brought about by intensified market competition.

　　(C) the risk of declining market demand for implantable orthopedic medical devices

　　In recent years, with the acceleration of social aging in China, the number of patients with orthopedic diseases has accelerated, and the market scale of implantable orthopedic medical devices has also increased. In this context, during the reporting period, the company’s sales model increased year by year and maintained a high growth rate. If the disease spectrum or treatment methods change in the future, the clinical demand for implantable orthopedic devices will decrease or the medical insurance budget will decrease, which will lead to the decline of the market model of the company’s main products, which may adversely affect the company’s operation.

　　(D) Risk of income growth decline or fluctuation

　　From 2018 to 2021, the company’s operating income increased rapidly year by year, maintaining a good upward trend. Affected by the epidemic in 2020-2021, the growth rate of the company’s operating income declined. In the future, the company may fail to effectively expand sales channels, increase market share or promote R&D projects due to changes in macroeconomic environment, repeated epidemics, intensified product market competition and poor internal management of the company. The above situation may lead to a decline in the growth rate of the company’s operating income or a certain degree of fluctuation.

　　In September, 2021, the state organized the Joint Procurement Office of High-value Medical Consumables to publicize the results of this national procurement with quantity, and the terminal prices of the products to be selected by Chunli Medical and other selected manufacturers all dropped significantly. It is expected that the price reduction pressure will be further transmitted to the distribution price after the implementation of the procurement with quantity in the future. If the increase in the company’s sales volume cannot make up for the decline in the distribution price, the company may experience a decline in revenue and profits.

　　(E) Risk of supplier dependence

　　From 2018 to 2021, the company’s largest supplier accounted for a relatively high proportion of the total procurement in the current period. The specific products purchased by the company from CeramTecGmbH are ceramic ball heads, ceramic linings, etc. During the reporting period, the company increased the promotion of high-end products such as ceramic joint prostheses. In view of the high stability requirements of ceramic joint prostheses, the company chose CeramTecGmbH as the qualified supplier of ceramic parts of the company, and did not purchase similar products from other suppliers, so there was some supplier dependence. If we can’t reach an agreement with CeramTecGmbH on commercial terms in the future, or because of natural disasters, international trade disputes and other force majeure factors, CeramTecGmbH can no longer provide ceramic ball heads and ceramic linings to the company, which will adversely affect the company’s production and operation.

　　(VI) Lease risks of production and business premises

　　During the reporting period, part of the real estate used by the company for production and operation was acquired through leasing. If the lease cannot be renewed normally upon expiration, the rent is greatly increased during the lease renewal, or the lessor breaches the contract during the lease process, it may have a certain adverse impact on the normal production or operating costs of the company.

　　(seven) the risk of core materials relying on a single overseas supplier.

　　During the reporting period, the ceramic ball heads and ceramic linings used in the company’s ceramic joint prosthesis products were purchased from CeramTecGmbH. CeramTecGmbH is an advanced supplier of ceramic materials headquartered in Germany. Mainstream joint manufacturers at home and abroad, including Johnson & Johnson, Xerox, Stryker, Jiemai Bangmei, Aikang Medical, Chunli Medical and Weigao Orthopaedics, all purchase ceramic materials from the company. Due to international political and other force majeure factors, the supply of imported raw materials may be delayed, limited or the price may be raised. If the company can’t get enough raw material supply in time, the normal production and operation of the company may be adversely affected. At the same time, affected by international trade disputes, there is a risk that the purchase price will increase due to the increase of tariffs.

　　(VIII) external processing Risk

　　During the reporting period, the company’s spraying, basic machining, sterilization, surface treatment and other processes were mainly produced by outsourcing. If the company fails to effectively implement the outsourcing management measures, it may bring certain risks to product quality and delivery time; At the same time, if the outsourcing manufacturers fail to provide products with good quality and quantity according to the agreement, or violate the agreement, the company’s technical and commercial secrets will be leaked, which will have an adverse impact on the company’s production and operation.

　　(9) Risks not included in the procurement catalogue with quantity

　　In May 2019, the eighth meeting of the Central Committee for Deep Reform deliberated and adopted the Reform Plan for Managing High-value Medical Consumables. In July of the same year, the General Office of the State Council issued the Reform Plan for Managing High-value Medical Consumables, proposing: "For high-value medical consumables with large clinical consumption, high purchase amount, mature clinical use and produced by many enterprises, we should explore centralized procurement according to categories, encourage medical institutions to jointly carry out quantity negotiation procurement, and actively explore cross-provincial alliance procurement. Many provinces across the country have successively carried out pilot procurement of high-value consumables. On November 20th, 2020, the National Medical Insurance Bureau’s Medical Price and Bidding Guidance Center issued the Notice on Developing the Fast Data Collection and Price Monitoring of the Second Batch of Centralized Procurement of High-value Medical Consumables. The products involved in the second batch of centralized procurement include the following categories: artificial hip joint, artificial knee joint, defibrillator, occluder, orthopedic materials and stapler.

　　On April 1st, 2021, the Office of Joint Procurement of High-value Medical Consumables organized by the State issued the Notice on Information Collection of Some Orthopedic High-value Medical Consumables. On the basis of collecting the purchasing data of medical institutions in the early stage, in order to further understand the market situation of orthopedic high-value medical consumables, it is planned to carry out the information collection of orthopedic high-value medical consumables in batches. The first batch of high-value medical consumables such as artificial hip joint and artificial knee joint were collected.

　　On June 21st, 2021, the Office of Joint Procurement of High-value Consumables organized by the State issued the Announcement of National Centralized Procurement of Artificial Joints (No.1), and on August 23rd, 2021, it officially issued the Procurement Document of National Centralized Procurement of Artificial Joints, giving a comprehensive explanation on the product categories, procurement rules and bidding rules of this centralized procurement. The company won the bid for group A of ceramic-ceramic hip joint product system, group B of ceramic-polyethylene hip joint product system and alloy-polyethylene hip joint product system, but failed to win the bid for initial total knee replacement. The company’s inventory is relatively high, and it failed to replace the artificial total knee joint product system for the first time in the national procurement bidding with quantity. If the company can’t take corresponding remedial measures, the market demand will drop rapidly, and the company’s related products will face the risk of unsalable sales that are not included in the procurement catalogue with quantity.

　　(ten) the spine business scale is small, and the risk of losing the bid in the procurement with quantity.

　　At present, many provinces in China have implemented the purchasing policy of joint products, and Anhui Province has also introduced the purchasing of spine products. In the future, more provinces may introduce the purchasing of spine products. The overall scale of the company’s spine business is small, which has a certain impact on the company’s spine products to participate in the procurement with quantity, and there are certain disadvantages in the bidding competition, so investors should pay attention to the related risks.

　　(eleven) the uncertainty risk in the process of import substitution.

　　Although the overall gap between domestic orthopedic implantable medical device companies and international orthopedic implantable medical device giants is narrowing year by year, in the domestic and international markets, international giants still occupy the dominant position with strong technical strength, research and development capabilities, capital supply capabilities, brand influence and higher trust. With the gradual advancement of import substitution trend, both sides are also in a state of coexistence of competition and cooperation. In the process of import substitution, there is a certain gap between the company and international giants in terms of business scale, product technology, production capacity and brand building, and they will face certain challenges. In the future, the company will have certain uncertain risks in the process of import substitution.

　　(V) Financial risks

　　(A) the risk of a large balance of accounts receivable

　　From 2018 to 2021, the company’s accounts receivable balance continued to grow. If major adverse changes occur in the operating conditions of major customers and industry settlement methods, it may lead to overdue accounts receivable, bad debts or further extension of the accounts receivable recovery cycle, thus adversely affecting the company’s sustainable profitability.

　　(VI) Industry risks

　　The company is mainly engaged in the research and development, production and sales of implantable orthopedic medical devices, and its medical device industry must be fully supervised and managed by the National Development and Reform Commission, National Health Commission, National Medical Products Administration and other competent departments. Domestic enterprises engaged in research and development, manufacturing, management and use of medical devices should follow the regulations of medical device product classification management system, medical device product registration system, medical device production enterprise filing or licensing system, medical device management enterprise filing or licensing system, medical device management quality management standard, etc. The export sales of medical device products are also affected by the relevant policies of importing countries.

　　In recent years, policy changes at home and abroad have also caused multiple policy risks to the company, including:

　　(A) "quantity procurement" brought about by the risk of product terminal price decline

　　In July 2019, the General Office of the State Council issued the Notice on Printing and Distributing the Reform Plan for the Management of High-value Medical Consumables, exploring "procurement with quantity" in the field of high-value medical consumables. Up to now, Anhui, Zhejiang, Jiangsu, Fujian, Shandong and other provinces have issued and implemented the policy plan of "procurement with quantity" and implemented the bidding procedures involving joint products. Except for the company’s failure to win the bid for the "quantity procurement" of hip joints in Jiangsu Province in 2019, the "quantity procurement" of other provinces and related joint products won the bid. According to the current situation of winning the bid, the winning bid price of related products has mostly decreased to a certain extent compared with the price before "purchasing with quantity", which further led to a certain degree of decline in the ex-factory price of the company in some provinces.

　　In June, 2021, the National Joint Procurement Office of High-value Consumables issued the Announcement of National Centralized Procurement of Artificial Joints, Announcement of National Centralized Procurement of Artificial Joints (No.1), and in August, 2021, it officially issued the Procurement Document of National Centralized Procurement of Artificial Joints, and carried out the bidding work of national procurement of initial total hip replacement and initial total knee replacement. September 2021

　　In June, the state organized the Joint Procurement Office of High-value Medical Consumables to publicize the results of this national procurement with quantity. According to the public information, the average price of the hip joint terminal to be selected dropped by 80%, and the average price of the knee joint terminal dropped by 84%. The company successfully won the bid for "Ceramic-Ceramic Hip Joint Product System", "Ceramic-Polyethylene Hip Joint Product System" and "Alloy-Polyethylene Hip Joint Product System" at a relatively high price, but the price was significantly lower than that before the "quantity purchase". The company’s "knee joint product system" failed to win the bid because of its high quotation. The decline in the price of hip joint terminal and the failure to win the bid for knee joint will be transmitted to dealers and companies, and the subsequent distribution price of the company will also be reduced. If the increase in sales volume cannot make up for the decline in distribution price, the company may experience a decline in revenue and profit. In addition, if the company’s distribution price is too high, squeezing the dealer’s profit will affect the dealer’s willingness to cooperate, or returning the goods due to the termination of the dealer’s business with the company and negotiation, it may have a certain impact on the company’s profitability.

　　(B) The risk of knee joint products failing to win the bid for national procurement with quantity.

　　On September 14th, 2021, the State organized the Joint Procurement Office of High-value Medical Consumables to publicize the selected results of the national procurement of artificial joints, and the company failed to win the bid in the "knee joint product system". In 2021, Beijing Bestar Biotechnology Co., Ltd. (hereinafter referred to as "Bestar") obtained the "Record Certificate for Entrusted Production of Medical Devices" issued by Beijing Drug Administration, allowing our company to produce Bestar’s knee prosthesis as the trustee. Bethesda’s knee joint prosthesis won the bid in this collective procurement, and our company obtained the power of attorney from Bethesda (No.:BSD21-09- China -01-265), which authorized our company to sell its knee joint products in People’s Republic of China (PRC). Through the cooperation with Bestar, our company reduced the decline in profitability caused by the failure of our knee joint products to win the bid.

　　(C) Risk of changes in domestic and foreign industrial policies

　　The company is a medical device manufacturer, and its domestic sales revenue is the main source of its main business income. The domestic business development is strictly supervised by National Medical Products Administration and other competent departments. In 2018, the National Health and Family Planning Commission and other six ministries and commissions jointly issued the Notice on Consolidating and Breaking the Achievements of Supplementing Medicine with Medicine and Deepening the Comprehensive Reform of Public Hospitals, further clarifying the implementation of the "two-vote system" for the purchase and sale of high-value medical consumables. With the change of the sales model brought about by the two-vote system, the company is faced with changes in operating conditions such as longer receivable payment cycle and increased sales expenses corresponding to unit sales revenue. If the company fails to formulate effective countermeasures in time according to the changes in the "two-vote system" policy, it may have an impact on the sales and operation of its products.

　　In addition, policies such as medical insurance reimbursement and centralized procurement have been introduced in China, and policies such as DRGs and "one-vote system" have been actively explored. In 2021, eight ministries and commissions, including the National Medical Insurance Bureau and the National Health and Wellness Commission, jointly formulated the "Pilot Program for Deepening the Reform of Medical Service Price", with the goal of exploring and forming replicable and scalable medical service price reform experience through three to five years of pilot. In addition, the company is also actively exploring foreign markets, and the development of overseas business is strictly supervised by the competent authorities of relevant countries and regions. For example, the new version of the medical device regulation MDR passed by the European Union in March 2017, at this stage, some matters in the new MDR regulations have not yet been clearly defined, and there are certain risks of policy uncertainty.

　　In the future, the importance attached to the medical device industry at home and abroad will be further enhanced, and relevant regulations and policies will be issued in the aspects of industry standards, bidding, centralized procurement and circulation system. If the company can’t keep up with the development of industrial policies, study the requirements of new policies in advance, do a good job in coping with the New Deal, and continue to carry out technological innovation and product upgrading, the company may face the risk of falling product market prices, which in turn will lead to a decline in gross profit margin, which will adversely affect the company’s future profitability. The company will pay close attention to the trend of centralized purchasing policy, continuously strengthen production and management, enhance the company’s product innovation ability and comprehensive strength, strengthen market promotion, consolidate existing markets, develop new markets, and strive to increase market share.

　　(VII) Macro-environmental risks

　　In the future, the company may fail to effectively expand sales channels, increase market share or promote R&D projects due to changes in macroeconomic environment, repeated epidemics and intensified competition in the product market. The above situation may lead to a decline in the growth rate of the company’s operating income or a certain degree of fluctuation.

　　(8) Risks related to depositary receipts

　　(9) Other major risks.

　　

　　V. Main operations during the reporting period

　　The year 2021 is the year when China has built a well-off society in an all-round way, and it is also the first year of the 14 th Five-Year Plan. Standing at the historical intersection of the goal of "two hundred years", facing the global COVID-19 epidemic and the national joint "purchasing with quantity" environment, under the strong leadership of the board of directors, all employees of the company actively responded to the risks and challenges in operation, forged ahead, continued to reform, accelerated the research and development progress of new materials, new processes and new products, and actively expanded new pipelines to adapt to the new normal of epidemic and centralized procurement.

　　By December 31, 2021, the company achieved an operating income of 1,108,139,500 yuan in 2021, an increase of 18.18% year-on-year; The net profit attributable to shareholders of listed companies and the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses were 322,360,700 yuan and 307,693,000 yuan respectively, with year-on-year increases of 13.76% and 11.22% respectively.

　　The company’s main operating conditions are normal and its operating performance is stable. There have been no major changes in the company’s business model, the purchase scale and price of major raw materials, the production and sales scale and price of major products, the composition of major customers and suppliers, tax policies, etc., and there have been no other major events that may affect investors’ judgment.

　　VI. The Company’s Discussion and Analysis on the Company’s Future Development

　　(A) the company’s development strategy

　　Relying on the national industrial policy of encouraging domestic (or) instrument products, and relying on years of accumulated industry experience and technical advantages, the company is committed to developing and producing joint prostheses, spinal implants and other products with excellent performance, and strives to become a world-class comprehensive medical orthopedic instrument manufacturer as soon as possible.

　　(3) Business plan

　　1, the rational use of capital market financing tools to enhance the company’s financing ability.

　　With the help of the capital market platform, the company will broaden the channels of capital operation, enhance the visibility of enterprises, enhance the ability to resist risks, enhance competitiveness and industrial integration, and rationally use the financing tools in the capital market to enhance the company’s financing ability, which is conducive to further promoting the company’s business development and helping the company’s long-term sustainable development in the future.

　　2, continuous talent introduction and training, to create a compound professional talent echelon.

　　The company will continue to implement the people-oriented human resources strategy, introduce and effectively cultivate compound talents on the basis of the existing talent team, cultivate cross-knowledge structures in marketing and academic promotion, research and development, production and comprehensive management, and establish a marketing system with flexible organization and project management as the leading direction to meet the needs of the rapid development of the industry and the company. The company will further establish a standardized and professional training system, strengthen employee on-the-job training and follow-up education and training, fully mobilize the enthusiasm and creativity of employees, give full play to their potential, and actively cultivate their expertise to achieve sustained and healthy development with the company.

　　3. Improve the construction of R&D platform and effectively promote the overall layout of products.

　　Based on the existing R&D capabilities, the company plans to build a multi-functional R&D platform that can meet the company’s long-term R&D requirements, and improve the company’s independent R&D capabilities and new product R&D efficiency. In the future, after the R&D center project of the company is completed and put into use, the company will make full use of advanced hardware conditions, rationally use R&D funds to effectively invest in the research and development of new products, improve the R&D transformation ability, further enrich and optimize the company’s product pipeline, and better provide orthopedic implanted medical devices with high quality and strong applicability for patients with orthopedic diseases.

　　4. Improve the construction of marketing network.

　　In the future, the company will further improve its marketing network, meet the growing demand of the downstream market and consolidate and expand its market share in combination with the expansion of its production capacity.

　　After the completion of the new marketing network project, the coverage and radiation level of the company’s marketing network will be further strengthened. The construction of marketing training center will provide systematic support for the clinical promotion and doctor training of the company’s products, and promote the brand promotion of the company in an all-round way and enhance the brand image of the company. The rapid expansion of marketing and distribution outlets will help the company quickly respond to the needs of terminal medical institutions and provide matching products for personalized orthopedic surgery in time. The marketing network information system, the newspaper station system and the customer management system will further strengthen the company’s management ability to customers, distributors and terminal hospitals and improve the level of information management.

Guangdong Medical Insurance Mingdian [2020] No.2

At the local level, the Municipal Health Insurance Bureau, Finance Bureau and Health and Wellness Bureau (Committee) are listed:

　　Now, the Supplementary Notice of the Office of the National Medical Insurance Bureau, the General Office of the Ministry of Finance and the General Office of the National Health and Wellness Commission on Doing a Good Job in Medical Security of Pneumonia Epidemic in novel coronavirus (No.6 [2020] of the National Medical Insurance Bureau) is forwarded to you, and the following opinions are put forward in combination with the actual situation in our province. Please implement them together.

　　First, increase medical security.During the epidemic period, confirmed suspected and confirmed insured patients, hospitalization and outpatient expenses of drugs and medical services that meet the diagnosis and treatment plan of pneumonia infected in novel coronavirus formulated by the national and provincial health administrative departments were all temporarily included in the scope of medical insurance fund payment, and the hospitalization Qifubiaozhun was cancelled. After the medical expenses of patients are paid in accordance with the regulations, such as basic medical insurance, serious illness insurance and medical assistance, the personal burden will be subsidized by the finance. Among them, the funds needed for the personal burden of the diagnosed patients are paid in advance by the hospital, with the central financial subsidy of 60%, and the remaining 40% is paid in advance by the finance at the same level in the place where the patient is treated. At that time, the provincial finance will co-ordinate the funds above the provincial level and settle them in different files according to the relevant requirements of basic public health services; Confirmed suspected patients are paid in advance by the finance at the same level in the place where they seek medical treatment, and the provincial finance co-ordinates funds above the provincial level to give appropriate subsidies as appropriate.

　　Second, ensure timely and smooth settlement.It is confirmed that the medical expenses of suspected and diagnosed insured patients are not included in the total budget control index of medical institutions, and hospitalization and outpatient services are paid according to the project. The diagnosis code of pneumonia in novel coronavirus temporarily uses joint code, that is, the main code J12.800 plus the additional code B97.200. Municipalities’ medical insurance agencies can temporarily increase the amount of advance payment for the pneumonia treatment hospitals infected in novel coronavirus, take various measures to solve the problem of differences between temporary policy adjustment and medical insurance information system, and timely settle the medical expenses of insured patients in line with regulations. Conditional areas should promptly add two temporary medical insurance settlement directories of "drugs for diagnosis and treatment of pneumonia infected in novel coronavirus" and "projects for diagnosis and treatment of pneumonia infected in novel coronavirus" to the medical insurance information system for the use of hospital settlement. For patients who seek medical treatment in different places, they shall be treated first and then settled, and the reimbursement shall not be reduced. Medical insurance agencies should coordinate medical institutions, do a good job in recording the information of insured patients seeking medical treatment in different places and accounting for medical expenses, and the medical expenses for medical treatment in different places in the province shall be settled with medical institutions in time by the medical insurance agencies in the insured places; Inter-provincial medical treatment in different places shall be carried out in accordance with the relevant provisions of the state, and liquidation shall be organized in a unified way throughout the country after the epidemic ends. The part that should be paid by individuals shall be settled with medical institutions in a timely manner by financial departments at all levels.

　　Third, continue to do a good job in the procurement and price monitoring of drugs and medical consumables.Municipal medical insurance departments should keep information flowing with procurement platforms and medical institutions, and jointly do a good job in the procurement, supply and price monitoring of drugs and medical consumables related to epidemic prevention and control. Instruct medical institutions to issue orders directly to the procurement platform in time for drugs, medical consumables and in vitro diagnostic reagent products related to novel coronavirus. Drugs and medical consumables that are difficult to purchase can be independently purchased by medical institutions for emergency use. At the same time, we should pay close attention to the price and supply changes of related drugs and medical consumables, and report to the Provincial Medical Insurance Bureau in a timely manner if the procurement supply and price situation are abnormal.

　　Fourth, strengthen departmental communication and coordination.Municipal medical insurance, finance, health and health departments should strengthen information exchange and share relevant data such as the number of inpatients and outpatients of suspected and confirmed patients every day. Medical insurance, health and health departments do a good job in the statistical work of medical expenses of insured patients and non-insured patients respectively. Medical and health institutions at all levels should standardize the process of confirmation and diagnosis of suspected and confirmed patients, and establish relevant statistical ledgers. Since January 28, 2020, the system of "daily submission and zero report" of medical insurance fund payment information will continue to be implemented. Municipal medical insurance departments should submit the epidemic situation and medical insurance fund, medical assistance fund payment and prepayment to the provincial medical insurance center before 10:00 every day.

　　If the original documents are inconsistent with this notice, this notice shall prevail. Major problems and situations encountered by cities in their work, please report to the Provincial Medical Insurance Bureau, the Department of Finance and the Health and Wellness Committee in a timely manner.

Guangdong Provincial Medical Security Bureau　　

Guangdong Provincial Finance Department

Guangdong Provincial Health and Wellness Commission

January 30, 2020

　　Attachment:Supplementary Notice of the Office of the State Medical Insurance Bureau, the General Office of the Ministry of Finance and the General Office of the State Health and Wellness Commission on Doing a Good Job in Medical Security for Pneumonia Infected in novel coronavirus

Original New Youth New Youth Non-fiction Writing Market is included in the topic # # Light and Shadow Puzzle 2# New Youth 44# Non-fiction Writing 46# College Students 37

This article is the course assignment of "Film and Television Culture and Criticism" of School of Journalism and Communication, Peking University in 2019, and won the excellent work award of "Light and Shadow Puzzle 2019 New Youth Non-fiction Writing Market".

Author | Zhang Yunling Lan Wenhao Tan Ting Sun Shuo

Instructor | Zhang Huiyu

Charlotte, a traveler in goodbye mr. loser, made a fool of herself at the age of 30 by relying on her wife for a soft meal. She was caught pretending to be a big spender at the wedding of Qiu Ya, her crush as a student.

Wang Duoyu, the goalkeeper in "The Richest Man in Xihong City", is full of football dreams but hangs out in the third-class amateur team. He was expelled from the team because of the defeat of the game and fell into a desperate situation.

Zhang Chi, a racing driver in "Flying Life", once dominated the racing world, but was banned for five years for illegal racing. He had to rely on fried rice to support himself and his son. In his late forties, he was eager to return to the racing field, but he was frequently hit in the face by reality.

Dafei, a liquor seller in Crazy Alien, is a liquor seller who has not won the agency. He is bent on making a fortune, but even has to steal money from his brother Geng Hao’s purse when he is poor.

Down and out, frustrated, arrogant and self-abased, which can be said to be the standard of all movie protagonists starring Shen Teng, but Shen Teng’s initial life orientation is actually not such a middle-aged diaosi.

01

It makes people laugh and cry.

Atypical "Military Art School Grass"

On October 16th, 1979, Shen Teng was born in a well-off family in Qiqihar, Heilongjiang. His parents named him Teng, which originally had the meaning of "soaring". But when I was a child, Shen Teng seemed to have nothing to do with "soaring" except noisy.

Naughty and loquacious, with poor grades, when high school is about to graduate, Shen Teng has no clear direction for his future life: "I am a person with no ambition, and I don’t expect to be as successful as my name.".

Applying for military arts comes more from family factors. Shen Teng’s elder sister is a soprano from a military background. In her opinion, since my younger brother has no plans for the future, it is better to apply for military arts like himself, and at least be a soldier in any case.

So, with the simple idea of mixing an "iron rice bowl", Shen Teng was admitted to the military art in a muddle.

"I was a school grass in military art, and later I was Yang Yang."

The self-mockery in this interview successfully sent Shen Teng to the hot search, and many people even regarded this interview video as a funny clip of the year. Whether there is the title of "school grass" is impossible to verify, but judging from the photos and interview videos of Shen Teng in his early years that can be found at present, Shen Teng was indeed a "beautiful teenager" when he was young. And Shen Teng is indeed a man of the hour in the military arts.

During the period of military art, Shen Teng appeared on the cover of Life of the People’s Liberation Army magazine.

Military art turned on Shen Teng’s performance switch. In the performance class, Shen Teng, who was first exposed to the stage and whose acting skills were still immature, performed the work "Ten-year-old Me", which was praised by the teacher unexpectedly. After this performance, Shen Teng was elected as the representative of the performance class. This modest official suppressed Shen Teng’s impetuousness, and also inspired him to learn how to perform well. Being fun by nature, he began to practice diligently. Shen Teng’s almost innate talent for comedy gradually emerged in college. Later, as soon as he stood on the stage, his classmates began to laugh, often making the audience laugh their heads off. Everyone seemed to equate Shen Teng with humor.

Teacher Liu Na took the lead in expressing the affirmation of Shen Teng’s comedy talent: "You don’t need to cultivate your comedy things for four years in college. You have enough comedy talent, but you have to play tricks to understand it. If you just play comedy, the road will be a bit narrow. " This sentence has a great influence on Shen Teng. After many years, Shen Teng insisted on comedy, but at the same time, he never relaxed his training of lines and performances, and constantly put forward new requirements for himself to broaden his play style.

The lines teacher also suggested to Shen Teng, who speaks fluent Northeast dialect: "If you can refuse Northeast dialect, you can speak Mandarin well, and you will develop in the future. You see that the teacher is also from the northeast. " I didn’t know that Shen Teng was outspoken. "Teacher, I heard it." The teacher didn’t expect him to be so straightforward, almost humiliating on the spot, and laughed and laughed at the student who brought his own jokes when he spoke.

Four years of military art career, theoretical study and skill training have given Shen Teng rich comedy materials, consolidated his comedy skills and laid a solid foundation for his future creation and performance.

02

Mahua FunAge:

Accumulated wealth and thin hair after common troubles

In 2003, Shen Teng graduated from the Department of Military Arts Performance. Surprisingly, when the students were busy with the cast and signing the company, Shen Teng, the former representative of the performance class, chose to join a little-known drama club-Mahua FunAge.

Today, Mahua FunAge is already the most market-oriented private organization in the field of stage play in China, but when Shen Teng joined, Mahua FunAge was just a small drama club with only more than 10 cast members.

I’ll Twist You If I Want to Eat Twist is Shen Teng’s first stage play in Mahua FunAge. Shen Teng played a slightly greasy ceremony host in the play. Dressed in a jumpsuit studded with sequins, he stood in front of the standing wheat in the center of the stage and interacted with the audience with exaggerated body movements and a very performative tone, as if they were really the audience who came to attend the ceremony. Close-up, Shen Teng unconsciously sipped his lips, micro-locked his brow, and cocked his head to the big star played by He Jiong, but he didn’t dare to show it again.

"I’ll give you a twist if I want to eat a twist" received a good response, which also laid the foundation for Mahua FunAge’s "grounded comedy" style in the future. But the opposite of good reputation is the poor performance of profitability. Because the stage play belongs to minority art, with low popularity and high cost, Mahua FunAge has been in a bleak business situation for a long time. Many times, a performance has only a few dozen spectators. In the most deserted performance, there were only seven spectators sitting under the stage in the huge theater. The theater manager couldn’t stand it anymore. "Why don’t you stop acting and refund the tickets to these audiences, and I won’t charge you rent." So, on that snowy winter night in Beijing, several Mahua FunAge leaders stood at the entrance of the theater to refund tickets to the audience one by one, and subsidized the travel expenses.

Poster of "I want to eat twist for you now"

An initial performing arts team often requires its members to be multi-skilled, and then establish their respective positions through years of tempering, which is also used to withstand the turmoil brought about by the coming and going of members. It is in this turmoil that Shen Teng changed from an actor to a screenwriter and director and returned to an actor. In the days when there were few people, he stayed up all night writing, writing at night and sleeping during the day, which made him suffer from severe osteoporosis. Even doctors were curious: "What does this big boy do? He can’t even see the sun every day." Even so, Shen Teng still has no choice to leave. "I am optimistic about Mahua FunAge and have feelings with team members. It is impossible to abandon them when they are in trouble."

From the age of 22 to 34, Shen Teng spent nine years in obscurity in Mahua FunAge before boarding the Spring Festival Gala. On the stage that has been cold for many years, Shen Teng silently polished his acting skills, diluted the excess desire and thirst for fame and fortune a little bit, and waited for the accumulation.

In 2009, the stage play Somali Pirates, which was officially directed by Shen Teng for the first time, won a good box office, and Mahua FunAge made a profit for the first time, and the company began to run on the right track. In 2010, Shen Teng starred in Mahua FunAge’s New Year’s Eve stage play Earl of Wulong Mountain as the leading actor for the first time. Mahua FunAge’s reputation is getting louder and louder, with a certain number of regular audiences. Everything began to develop in a good direction, and both Shen Teng and Mahua FunAge were waiting to shine more brilliantly on a bigger stage.

Shen Teng’s first stage play Somali Pirates.

Shen Teng starred in Mahua FunAge’s play The Count of Monte Cristo.

03

From the New Star of the Spring Festival Evening to the Happy Comedian;

Don’t want to just be "Hao Jian"

The Spring Festival Gala in the Year of the Loong in 2012 has a turning point in many aspects.

That year, the general director of the Spring Festival Gala changed. Ha Wen took the banner from Chen Linchun, Liu Gang and Ma Dong, and became the general director of the Spring Festival Gala for the first time.

It was also that year that Zhao Benshan, an evergreen tree in the Spring Festival Evening, disappeared into the rehearsal hall of the Spring Festival Evening after boarding CCTV Spring Festival Evening for 17 consecutive years. "No Benshan, no Spring Festival Evening", Uncle Benshan’s weight in previous Spring Festival Evening stages is beyond doubt. Whether it is the tacit cooperation with the "Iron Triangle" or the "White Clouds and Black Soil" couple in Song Dandan, it is a classic of the times that is difficult to reproduce. With the rural economic system reform and urbanization as the background, Uncle Benshan, with his unique life experience rooted in the fields and the humor and wit of folk art, has been recognized as a national comedy image for many years.

However, the torrent of the times is pushing forward with people’s constant refreshing of comedy aesthetics. After 2010, with the deepening of reform and opening up and the development of market-oriented operation mode, the audience market of sketches has also changed with the changes of audience’s aesthetic preferences. For a new generation of audiences, Uncle Benshan’s image as a simple and honest grass-roots farmer who tries to integrate into the modern trend is no longer their existing experience. On the other hand, the excessive use of northern dialects in Benshan sketches has also made some southern audiences "unable to eat" and even triggered a dispute about the use of dialects in the Spring Festival Evening. The "black soil", which has been active for more than ten years in the Spring Festival Evening, gradually seems a bit vague and boring.

It is the Mahua FunAge team represented by Shen Teng who "took over" Uncle Benshan at this time node.

Mahua FunAge’s sketch for this year’s Spring Festival Gala is called Happiness Today. As a pillar of Mahua FunAge, Shen Teng plays the role of pretending to be Hao Jian, the "son" who came back from the future to visit his parents. That year’s Spring Festival Gala, when Shen Teng poked his head out from the fake TV set with a full face of surprise and stretched out a hand to say hello while enthusiastically shouting "Dad", the applause thundered under the stage.

Shen Teng plays "son" Hao Jian in the essay "Happiness Today".

This sketch made Mahua FunAge’s team gain a firm foothold in the Spring Festival Evening stage, and the role of "Hao Jian" played by Shen Teng became a household name overnight.

Urbanized stage art, more acceptable pronunciation of Putonghua, and the characterization of various diseases of contemporary young people all make Mahua FunAge a "dark horse" in the history of Spring Festival Evening sketches. The following year, Mahua FunAge made persistent efforts to return with Happiness Today 2. Hao Jian has also returned. That year, Shen Teng leaned against the window and said awkwardly and naughtily, "It’s not innocence that defeated you, it’s no shoes (evil)", which became a classic bridge in the Spring Festival Evening. The voice of Uncle Benshan’s comeback in the Spring Festival Evening has gradually been drowned out in the comments and spit on the Spring Festival Evening in the new year.

People’s favorite literary and artistic works will have more opportunities to be displayed. From 2012 to 2015, as the core role of Mahua FunAge’s sketches, Shen Teng has been on the stage of the Spring Festival Evening for four consecutive years, and performed the image of "Hao Jian", a middle-aged "nobody", which brought joy to the audience, but also made many people find their own shadow in it more or less, and became another distinctive identity symbol after Peisi Chen’s reform youth and Zhao Benshan’s migrant farmers.

Stills of "Today’s Happiness 2"

"Hao Jian" has become the second identity of Shen Teng, and many people even know only "Hao Jian" but don’t know Shen Teng. Although it is often new, it is actually an embarrassing experience for Shen Teng. "Hao Jian has made me, but I am really not satisfied with expressing a Hao Jian all the time. I also want to express different lives and experience the fate of different characters."

In order to break the role label of "Hao Jian" and try more diverse comedy performances, in 2015, Shen Teng took part in the variety "Happy Comedian" with his team.

At this time, Mahua FunAge has become a comedy team of its own in China, with a small number of fans, and the attendance rate of stage plays is much higher than that of similar domestic drama clubs, and sometimes even a ticket is hard to find. Coupled with several years’ performance experience in Spring Festival Evening skits, compared with other groups, Shen Teng’s Mahua FunAge team has an incomparable sense of advanced satire in comedy performance.

"The essence of comedy is satire and criticism, not pure comedy." This is Shen Teng’s own interpretation of comedy.

In the semi-final, Shen Teng team chose to pay tribute to the comedian Chaplin with his work Where is the Thief. In order to enhance the expressive force, on the eve of the competition, Shen Teng urged all the people to delete all the lines and let them rehearse in the form of mime overnight. In a crowded carriage, each character was portrayed by pure body movements and expressions.

Shen Teng played Chaplin himself. Through the eyes, expressions and movements, in the short play of less than ten minutes, Shen Teng showed every psychological detail of Chaplin vividly. At the end, "Chaplin", misunderstood by the audience, sat in front of the window, his hands clasped helplessly and his chin stood on tiptoe. The sadness and injury revealed in his unfocused eyes deeply shocked the hearts of the audience and the judges present.

Shen Teng pays tribute to Chaplin with Where the Thief Goes.

Shen Teng won.

In July, 2015, Shen Teng led Mahua FunAge to win the annual championship of the first season of Happy Comedy, defeating the Liaoning Folk Art Troupe and the Jia Ling team led by Song Xiaobao. At this time, Shen Teng is no longer a dramatist who can only perform stage plays, but a highly plastic comedian who is meticulous in the script, has leadership for the team, and has his own thinking and understanding of comedy.

04

"New king of comedy"?

It was also in this year that the film goodbye mr. loser changed Shen Teng’s life again.

"goodbye mr. loser" is a daydream about a middle-aged diaosi who has accomplished nothing, crossing the past and achieving an ideal self completely different from reality. And Shen Teng is the key factor to test the water for Mahua FunAge to enter the film market.

Few people are optimistic about this lightweight film. However, it is this comedy film with a cost of only 20 million yuan. In 2015, it gained 1.44 billion yuan at the box office as a dark horse, ranking sixth at the box office of the year and third at the box office of domestic films. Shen Teng, 36, has become a rising star in the mainland comedy film Ran Ran.

But people didn’t wait for Shen Teng to explode. In the following three years, Shen Teng often appeared as a supporting role in Mahua FunAge’s films, like Zhang cornus, the deputy director who fell from the sky in Shame Iron Fist, adding a few Shen Teng-style humor to the film in several frames. However, in the past three years, he has never received any film first hero. He is unwilling to make do with the quality of the script and the role.

Shen Teng’s Stills in The Iron Fist of Shame

"As an actor, I think I can’t consume myself, I can’t consume this Hao Jian or Charlotte I am carrying, and I can’t consume my career."

Shen Teng waited for the role he wanted.

In the summer of 2016, "The Richest Man in Xihong City" was released. After three years of disobedience, Shen Teng officially returned to the film market with the role of Wang Duoyu.

My career is low, I’m down and out, I’m exhausted, and I’m a little shameless. Wang Duoyu, the goalkeeper in "The Richest Man in Xihong City", has many similarities with the role that Shen Teng is always good at shaping. Knowing that he can’t win and can’t keep the goal, he is not willing to accept the money for playing fake ball; Knowing that the other person looks down on himself from the bottom of his heart, he has to crush the other person with money in a competitive way, maintaining his final dignity and posture as a "local tyrant".

Shen Teng’s portrayal of Wang Duoyu’s role highlights the psychological struggle of the little people in him between dreams and reality, who are unwilling to show weakness but are extremely struggling. For example, when he saw 1 billion yuan, he sat down on the pulley chair with a dull face and couldn’t get up any more. For example, he used a tractor to pour money into the training ground of the football team that had fired him. For example, after learning that he had earned another 100 million yuan, he couldn’t help but fight hard. Shen Tengfu’s layered performance reflected his deep understanding of the inner feelings of this role and made the film show its meaning other than funny.

Wang Duoyu’s legs are weak after seeing 1 billion cash.

Wang Duoyu’s experience is another daydream story full of fairy tales. His body carries the most popular fantasies and exposes the deep irony of reality. And this kind of superficial confusion and sober collision behind it is the sharpest irony of money and reality in The Richest Man in Xihong City.

At the end of the film, Wang Duoyu in Xia Zhu’s fantasy is a knight who wears a robe of "thousands of dollars" and carries heavy money bags in his hands, and appears at the stairs of a building like a doomsday hero, personally breaking the fairy tale and saving the princess. The reality, however, is that Shen Teng is wearing that familiar yellow tracksuit, with messy hair and closed eyes. He is sitting on the steps and swearing with a runny nose and tears, crying his wrinkles together. But it is this disillusionment that makes the audience more realistic with a knowing smile.

This is a kind of comedy image that Shen Teng is good at creating. Whether it’s Charlotte, Wang Duoyu, Zhang Chi or Dafei, these little people are in their own difficult situation, timid, timid, arrogant and self-abased, but they are daydreaming, and there are precious qualities of justice, kindness and purity in them. They suffered the ups and downs of their lives when they were down and out, and lost their inner persistence at some moments in the process, but they always found this almost idealistic persistence at the last minute. The collision between idealism and reality is the starting point and the end result of Shen Teng-style comedy films.

The ending of The Richest Man in Xihong City

The movie role played by Shen Teng.

In 2019, Shen Teng’s Flying Life and Crazy Alien collided head-on with Stephen Chow’s New king of comedy. For a time, "Will Shen Teng surpass Stephen Chow" has become a hot topic in the streets.

In 1990s, Stephen Chow established his own unique comedy style of "Star Master" by virtue of his unique nonsense style, and was the king of box office with high spirits. It was an unrepeatable peak era that belonged exclusively to Stephen Chow.

But today, faced with the capital that has expanded countless times, more diverse media, complicated comedy genres and even "sharp" audiences with better tastes, Star Master’s nonsense comedies are no longer popular, and more people just take "The Mermaid" and "New king of comedy" as a tribute. Comparatively speaking, Shen Teng, which has successfully entered the box office of 12 billion with Flying Life and Crazy Alien, seems to be becoming the "king of comedy" of the new era.

Tang Ling, a famous film critic, said: "The core similarity of actors of this level is that not only their own acting skills should reach a high standard, but also they can reflect the national spirit in a period of time. The reason why their comedies make us laugh is because they are a reflection of the overall psychological state of society at that time."

Shen Teng grasped the needs of the audience, tried to dramatize those little people with typical faces in today’s society into their own representative roles, and successfully performed "base comedies" with the brand of the times. Self-mockery is not self-dwarfing, self-belittling, but maintaining dignity, laughing and cursing at the same time retaining a deep feeling style. Behind the seemingly absurd comedy, Shen Teng has an almost serious persistence in comedy. He wants the audience to see the irony under the absurdity of comedy and arouse their thinking and resonance through their own performances. These efforts have made more and more people agree with Shen Teng, a new generation of national comedian.

05

The national comedian has become a traffic bear.

In addition to movies and dramas, in recent years, Uncle Shen, who is "growing up with jokes", is more active in variety shows.

Actors are easily forgotten by the market if they don’t appear in public. After waiting for a suitable screenplay for three years, Shen Teng began to participate in various variety shows one after another for the sake of maintaining exposure and other considerations. From "Teng Mei" who was named as "the lazy king" in Let’s Cross, to Uncle Teng who expressed his deep affection for his wife in "The Son-in-law Comes to the Door", and then to the captain whose IQ often drops off in "Ace to Ace", Shen Teng is a funny person in many variety shows with the help of "funny skills like mudslides" and "walking funny machines". Today, whether as a resident guest or a flying guest, Shen Teng’s appearance can always become a hot search explosion point maker and a guarantee of ratings.

However, Shen Teng in the variety show did not find consistent happiness. In his view, frequent participation in variety shows is more like a kind of involuntary. "Acting in variety shows is much more tiring than performing on the stage, and countless shots just stare at you and laugh." Variety shows amplify Shen Teng’s innate sense of humor, as well as every detail except his jokes. We should always pay attention to the audience’s expectations, always remind ourselves that we are the people who grow up at the punchline and bear the aura that others have never had. Shen Teng must be careful in every step.

"It’s not as fun as it used to be."

This is Shen Teng’s evaluation of his development in recent years. In the past, he was "no one knew you, just an actor, and it was enough to perform his tricks in a down-to-earth way", but the reality pushed Shen Teng forward, and Shen Teng had a few more concerns in the public eye. "It is no longer a simple transmission of happiness, but a very competitive thing." He needs to participate in variety shows to improve his exposure, and he needs to be active in front of the screen to show himself. The entertainment market has attracted him a lot of attention, put more labels on his back, and created a funny role as Uncle Shen with a lens of national concern, which is mixed with reality and people.

In addition to frequently participating in variety shows, another big problem that puzzles Shen Teng is that he began to frequently board hot searches in Weibo.

On May 20, Shen Teng once again rushed to the hot search. This time, it’s only two days since the hot search topic of "Shen Teng’s colorful words were forgotten" was last "Shen Teng’s photo expression", but as of May 25th, the reading volume of this topic has reached 190 million.

Shen Teng’s Baidu search index is comparable to a certain traffic Hua Dan.

In fact, as early as the beginning of this year, Shen Teng’s name would appear on the hot search list every now and then, from "before Shen Teng was the school grass" to "Shen Teng was dissatisfied with the 21st most handsome man in Asia", and this "Uncle Treasure", which was called "the man with a funny face", suddenly reached the popularity of being comparable to some traffic stars. The national comedian "who grows on the punch line" has become not only the box office, but also the "traffic responsibility". In this era when Weibo’s hot search can be updated in 1 minute, Shen Teng doesn’t have to wait for the blockbuster on New Year’s Eve every year, nor does he have to wait for the comments after the movie is sold. He just needs to show his "meanness" in front of the camera as much as possible, show something different from others, and even send a Weibo, and millions of Weibo fans will help him return to the center of public vision.

The source of these heat is not mysterious. After all, the two films starring Shen Teng in this year’s Lunar New Year movie performed well, and Shen Teng’s own factors that can trigger the hot search explosion point, such as his appearance, his wrinkles, his family, his fans, and Shen Teng’s motionless in 2019, can all become hot topics. Nowadays, "fear of hot search in Shen Teng" has become the common aspiration of many fans in Shen Teng. Today’s Shen Teng has been unable to control the frequency of hot search.

Hot search related to Shen Teng

Getting Shen Teng to search online is also an important part of online marketing of movies and variety shows. "Maybe it needs hype, but it is too frequent after all" is a netizen’s evaluation of this phenomenon. It’s unknown whether there is a team behind the marketing or a meticulous "killing", but at least for the moment, Shen Teng has become a "favorite" comedy star, and at the same time, it has caused controversy whether he can be a "comedian".

Shen Teng once said that his happiest thing was "when Mahua FunAge was still wandering around in East Cotton Hutong and several places in Heping, a group of young people with no distractions drank wine and drank a string of words, thinking about their baggage day and night", but now, in the market, marketing and traffic, Shen Teng has made his own comedy signboard, which has won a huge number of fans and inexhaustible heat, but those who have no hot search.

In the new market environment, the entertainment circle needs marketing. The moment Shen Teng stepped off the stage of drama and walked into the TV screen, he was doomed to make waves in the torrent of this market. In this era of traffic first, Shen Teng could not pull away from it, nor could he change it. He could only try his best to keep his original heart in the face of impetuousness and nothingness, and keep his inner persistence and love.

But Shen Teng is lucky. He was born in an era suitable for filmmakers, especially comedy filmmakers. In a sense, this "man with a laugh" is a comedy hero shaped by the times. We don’t know whether Shen Teng will become the new "king of comedy" in the future, but it is undeniable that as a comedian and comedian, Shen Teng has won his time. Walking on the road of becoming a "national comedian", Shen Teng is leaving his mark in this era.

reference data

[1] beijing business today: "Shen Teng, king of comedy? 》

[2] Doing business: "Shen Teng smiles 12 billion"

[3] People: "Shen Teng: Laziness is my protective color"

[4] National Pavilion: "Shen Teng: Laziness is an innate strength".

[5] Talk about resources: "Shen Teng is the funniest if he doesn’t laugh."

[6] Iris: "Peisi Chen, Zhao Benshan, Shen Teng, who is the king of Spring Festival Evening sketches?"

[7] Iris: "The era of comedy movies in Shen Teng has just started."

[8] Once a day: "Shen Teng, how long will you stay on my punch line? [9] Prairie Girl: Shen Teng: All my ambitions are used for fun.

[10] Kapok micro-publication: "Shen Teng: Sometimes a fool, sometimes a genius."

[11] The Paper: "Shen Teng: not talking is also a kind of rest."

[12] Wu Tongyu. Shen Teng’s "Buddhist" life [J]. Labor and social security world.

[13] Xu Hailong. From "peasant sketch" to "citizen sketch"-CCTV Spring Festival Evening audience’s acceptance and sublation of Zhao Benshan sketch [J]. Media Watch, 2016(03):16-18.12

[14] Ji Li, Wu Yiyou. Accent discrimination and cultural discipline of social groups-A case study of accents in 30 years of Spring Festival Evening sketches [J]. Modern Communication (Journal of Communication University of China), 2015,37(07):81-85+146.

[15] Tang Dynasty. Analysis of Mahua FunAge’s comedy film creation mode-taking "The Richest Man in Xihong City" as an example [J]. Film Literature, 2018,713(20):103-105.

Original title: "Light and Shadow Puzzle, Shen Teng: National Joker in New Market"

Read the original text